Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

Search
Advanced Search
OPEN ACCESS
mobile search button mobile menu button

Articles

Page Path
HOME > Cancer Res Treat > Volume 50(1); 2018 > Article
Review Article The Generation and Application of Patient-Derived Xenograft Model for Cancer Research
Jaeyun Jung, MS1, Hyang Sook Seol, PhD2, Suhwan Chang, PhD1,
Cancer Research and Treatment : Official Journal of Korean Cancer Association 2018;50(1):1-10.
DOI: https://doi.org/10.4143/crt.2017.307
Published online: September 13, 2017

1Department of Biomedical Sciences, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

2Asan Institute for Life Science, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

Correspondence: Suhwan Chang, PhD Department of Biomedical Sciences, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul 05505, Korea
Tel: 82-2-3010-2095 Fax: 82-2-3010-8165 E-mail: suhwan.chang@amc.seoul.kr
• Received: June 23, 2017   • Accepted: September 8, 2017

Copyright © 2018 by the Korean Cancer Association

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

  • 26,979 Views
  • 1,155 Download
  • 204 Web of Science
  • 180 Crossref
  • 219 Scopus
next
Full Article

Download PDF Download PDF

  • Establishing an appropriate preclinical model is crucial for translational cancer research. The most common way that has been adopted by far is grafting cancer cell lines, derived from patients. Although this xenograft model is easy to generate, but has several limitations because this cancer model could not represent the unique features of each cancer patient sufficiently. Moreover, accumulating evidences demonstrate cancer is a highly heterogeneous disease so that a tumor is comprised of cancer cells with diverse characteristics. In attempt to avoid these discrepancies between xenograft model and patients’ tumor, a patient-derived xenograft (PDX) model has been actively generated and applied. The PDX model can be developed by the implantation of cancerous tissue from a patient’s tumor into an immune-deficient mouse directly, thereby it preserves both cell-cell interactions and tumor microenvironment. In addition, the PDX model has shown advantages as a preclinical model in drug screening, biomarker development and co-clinical trial. In this review, we will summarize the methodology and applications of PDX in detail, and cover critical issues for the development of this model for preclinical research.
  • Key words: Patient derived xenograft, Preclinical model, Immune deficient mouse, Personalized medicine
According to the report of World Health Organization and National Cancer Institute, cancer is defined as a group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body. In 2012, an estimated 14.1 million new cancer cases and 8.2 million cancer deaths occurred worldwide [1], that comprises 14.6% of total human deaths. Cancer is a leading cause of death worldwide in countries of all income levels. The number of cancer cases and deaths is expected to grow rapidly as populations grow, age, and adopt lifestyle behaviors that increase cancer risk [2]. In this aspect, cancer research needs to be performed in depth based on the model that better represents the exact characteristic of human cancer.
Cancer cell lines (CCLs) derived from patients have been used for not only in vitro but also in vivo experiments [3]. Especially, a xenograft model generated by the injection of these cell lines subcutaneously into immunodeficient mice is the most commonly used model in preclinical drug development [4]. This model is easy to generate and shows consistent tumor growth among animals. However, the xenograft model using CCLs has several limitations on the other hand. The first one is this model could not reflect the patient’s drug response sufficiently. The fact that successful clinical approval rate for cancer drugs is very low (approximately lower than 15%), especially in solid tumor [5] supports this idea. Second issue comes from an observation that most tumors contain highly heterogeneous subsets of cancer cells with different characteristics in one tumor. This is partly due to the genomic instability of cancer that increases the complexity of the cancer phenotype by the simultaneous alterations in several oncogenes and tumor suppressors [6]. Therefore, the xenograft model using CCL is not sufficient to represent the complex tumor heterogeneity. Moreover, tumor cell is often surrounded by fibroblast, vessel cells, and immune cells and interaction with these cells is a critical factor for the characteristics of each tumor. For example, this tumor microenvironment affects the growth and metastasis of cancer cells. However, the xenograft tumor often cannot recapitulate the tumor microenvironment.
To overcome these limitations, there has been increasing interest in patient-derived xenograft (PDX) model as a more advanced preclinical cancer model. In the PDX model, a tumor specimen is directly transplanted into immunodeficient mice, providing a faithful representation of individual tumor [7]. Although genetically engineered mouse model is also generally used as a preclinical model, it usually takes long time to develop and has less heterogeneity than PDX model because only few genes are modified. Therefore, PDX model is becoming a preferred preclinical tool in the drug development [8,9]. The translational cancer research is also facilitated by several collections of extensively characterized PDX model and it is regarded as a useful tool to apply the personalized medicine. In this review, we will cover current methodology for the generation of PDX models, summarize PDX model developed so far, describe the advantage of PDX model, and comment important issues for the future development of this model.
1. The process of generating PDX
PDX can be developed by the implantation of cancerous tissue from a patient’s tumor into an immunodeficient mouse directly. Several types of such mice can be used to establish PDX models: athymic nude mice, severely compromised immune deficient (SCID) mice, nonobese diabetic (NOD)– SCID mice, and recombination-activating gene 2 (Rag2)- knockout mice [10]. The mice used must be “immunocompromised,” to prevent graft rejection. The NOD-SCID mouse is more commonly used for PDX models than SCID because it does not produce natural killer cells [9]. However, recently, NSG (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ), mice are more preferred than any other strains. NSG has a complete null mutation in the gene encoding the interleukin 2 receptor gamma chain, which causes deficiency in multiple cytokine signaling pathway, leading to dysfunctions of many parts of innate immunity including natural killer cell differentiation [11]. Therefore, it is regarded as best model for the efficient engraftment of primary human tumor or tumor cells [12,13]. The advantages and disadvantages of each strain are summarized in Table 1.
There are two different input materials for the PDX generation. The first one is single-cell suspension and the second one is tissue fragment. Usually implanted tumor is gained when patient underwent surgery. The lesion of cancer is transported to pathologist or researcher in tube filled with culture media (Dulbecco's modified Eagle's medium [DMEM] or RPMI with 10% fetal bovine serum [FBS] and 1% penicillin/streptomycin). After that, the necrotic tissues are removed and the tumors are sectioned into smaller fragments, chemically digested, or physically manipulated into a single-cell suspension. There are advantages and disadvantages in utilizing either discrete tumor fragments or singlecell suspensions. Tumor fragments retain cell-cell interactions as well as some tissue architecture of the original tumor, therefore mimicking the tumor microenvironment. Alternatively, a single-cell suspension enables scientists to collect an unbiased sampling of the whole tumor, avoiding spatially enriched subclones that are otherwise inadvertently selected during analysis or tumor passaging [14]. However, singlecell suspensions subject tumor cells to harsh chemical or mechanical forces that may sensitize cells to anoikis, taking a toll on cell viability and engraftment success [15].
Unlike developing xenograft models using CCLs, there are no intermediate in vitro processing steps before implanting tumor fragments into mouse to create a PDX. When using CCLs, a sufficient amount of cells should be cultured before the injection into mouse. This in vitro step consumes large amount of time and effort. However, in the case of PDX, tumor fragments can be implanted immediately after obtaining tissue from patient without any culture. Instead, tumor fragments should be chopped into 2-3 mm3 for easier transplantation (Fig. 1). The tumor fragments are either implanted heterotopically or orthotopically onto the recipient mouse. Heterotopical implants occur when the tumor fragment is implanted into an area of the mouse unrelated to the original tumor site, generally subcutaneously or subrenal capsular sites [16]. In the orthotopic transplant, in contrast, scientists transplant the patient’s tumor tissue into the corresponding anatomical organ. Subcutaneous PDX rarely produce metastasis in mice and hardly simulate the initial tumor microenvironment [16]. Orthotopic model is difficult to generate, depending on organ, but it can mimic the natural environment of primary tumor, so it is thought as an ideal model. Ultimately, it takes about 2 to 4 months for the tumor to engraft. The latency varied by tumor type, implant location, and strain of immunodeficient mice utilized. The engraftment failure should not be declared until no tumor growth is observed for, at least, 6 months [10].
After tumor is harvested, most parts of tumor are cut into small pieces (1-2 mm3) and washed 3-4 times with culture media. Finally, the tissue is put in freezing media (FBS plus 10% dimethyl sulfoxide) and stored at -80℃. This stock can be used for re-transplantation into other mice later. The first generation of mice receiving the patient's tumor fragments are commonly denoted F0. When the tumor reached enough size, it is dissected and re-implanted into other recipient mice. Each generation thereafter is denoted F1, F2, F3, ..., and Fn. For drug development studies, PDX underwent more than F3 generation is often used, after ensure that the PDX has not genetically or histologically diverged from the original tumor [17]. When tumor saved at -80℃ is re-transplanted, the stock is thawed completely in 37℃ water bath and the tissue is put in plastic tube filled with 10-15 mL media (DMEM or RPMI containing 1% penicillin/streptomycin). These fragments of tumor are moved to petri dish for re-implantation.
2. Success rate for the generation of PDX model
Some companies have commercialized PDX model for almost all cancer types. Depending on the cancer type, the success rate of the xenograft varies. Based on previous reports, success rate and specific engraftment method are summarized in Table 2 [18-33]. The success rates of PDX are influenced by several factors. Firstly, the characteristics of primary tumor, such as the aggressiveness of tumor, histological type, and tumor cell percentage in the tissue, are considered important. For example, in the case of breast cancer, triple negative breast cancer shows higher success rate than other histological type like estrogen receptor-positive or human epidermal growth factor receptor 2-positive cancer [34]. Secondly, process for the generation of PDX can affect the success rate. Tissue should be as fresh as possible, meaning that time taking from surgery room to laboratory should be minimized. Also, the tissue needs to be kept in cold, fresh media immediately after surgery. Thirdly, the size and number of tissue implanted can be a factor affecting success rate. The greater number of pieces tends to increase success rate and fragment size should be 1-2 mm3. Fourthly, the location of implantation can make difference in success rate. Usually, implantation in subrenal capsule shows higher success rate than subcutaneous implantation because subrenal capsule maintains the original tumor stroma as well as the equivalent host stroma [35]. Notably, the ability of tumor to adapt to host environment varies by the original tumor. Tissues that adapt well to environment without immune rejection are more likely to succeed.
3. Validation and molecular analysis of PDX model
When the transplanted tumor reaches enough size (diameter of 1-2 cm), it should be harvested. During the harvest process, mouse tissue surrounding tumor should be removed as much as possible. After that, a portion of tumor is preserved in 10% formalin. To validate that the gross histology of the PDX is conserved with the original tumor, a paraffin block will be generated from the preserved tissue and will be stained by hematoxylin and eosin or other important immunohistochemical markers.
On the other hand, genomic DNA extracted from frozen tissue would be used for cancer panel or whole genome sequencing. RNA also would be purified for RNA sequencing or real-time polymerase chain reaction to measure the expression of specific genes. If the expression of proteins needs to be examined, protein can be extracted from the PDX tissue by chopping or grinding it with tissue-rupter.
1. Advantages of using PDX model
CCLs are originally derived from patient tumors, but has been extensively selected and changed to acquire the ability to proliferate in vitro. Because of the in vitro manipulation, CCL also gained genetic transformations that are not recovered when cells grow in vivo [36]. As a result of the process including enzymatic dissociation and centrifugation, cells that are adapted to survive in culture are phenotypically homogeneous [14]. Consequently, the tumor generated by injection of CCL is unlikely to retain the heterogeneity of its original tumor.
Researchers deliberated the reason why only 5% of anti-cancer agents are approved by the Food and Drug Administration after pre-clinical testing. As a result, the lack of tumor heterogeneity and the absence of the human stromal microenvironment affect high rate of failure [37]. Specifically, CCL-xenografts often are not predictive for the drug response of the primary tumors because it lacks the heterogenous molecular pathways of drug resistance existing in original tumor or the other cells comprising tumor microenvironment [37]. In other words, drugs usually target specific molecule or receptor in CCL and work efficiently as it consists of selected homogenous cells. However, in most primary tumors with heterogenous cancer cells with stroma, the response to the drug can be totally different.
To overcome this limitation, PDX models have been successfully established for breast, prostate, pancreas, colorectal, lung, and many other cancers for drug safety and efficacy studies as well as examining personalized response to certain anti-cancer agents [38]. Since PDX can be passaged without in vitro culture steps, PDX models allow the propagation and expansion of patient tumors without significant genetic transformation of tumor cells over multiple generations [39]. Within PDX models, tumor cells grow in physiologically-relevant tumor microenvironments that mimic the oxygen, nutrient, and hormone levels that are found in the patient’s primary tumor site [17]. Furthermore, implanted tumor tissue maintains the genetic and epigenetic abnormalities found in the patient and the xenograft tissue can be excised from the patient to include the surrounding human stroma [40]. As a result, numerous studies have found that PDX models exhibit similar responses to anti-cancer agents as seen in the actual patient who provided the tumor sample [41]. Hence, PDX model is beneficial to test therapeutic responses for certain drugs because multiple therapies can be tested against expanded PDXs generated from one biopsy and pretreatment and post-treatment data can be acquired from the xenograft tissues [40].
2. Application of PDX model in cancer research

1) Drug screening and biomarker development

PDX model has been generated and used in several retrospective studies and more recently in preclinical trials. Several researches using PDX model in breast cancer, renal cell cancer, non-small cell lung cancer (NSCLC), squamous cell carcinoma of the head and neck, and colorectal cancer showed that the drug response rates in PDX models correlate with those observed in the clinic, both for targeted agents and for classic cytotoxins. For example, in renal cell cancer, PDX model respond to the sirolimus and sunitinib and dovitinib, but not to erlotinib, which is the same as clinical data [42]. In addition, the response rate of epidermal growth factor receptor inhibitor cetuximab in PDX model was exactly identical with the results from clinic [18]. Similarly, an efficacy study for MEK and phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor in PDX model showed low response, which also coincide with clinical study [43]. With regard to conventional chemotherapy, studies in NSCLC, breast cancer, colorectal cancer, and pancreatic ductal adenocarcinoma demonstrated that PDX model showed comparable response rates for clinically used agents such as paclitaxel, carboplatin, gemcitabine, 5-fluorouracil, irinotecan, and adriamycin to clinical data [44].
More recently, the use of PDX models as potential screening platforms for clinical trials has been shown in a prospective study for pancreatic cancer. In PDX model, metformin treatment did not inhibit the growth of pancreatic cancer. Clinical trial also showed no benefit of adding metformin to combination therapy regimens targeting locally advanced and metastatic pancreatic cancer [45]. This is an example showing the data from preclinical test using PDX model could save time and resource required for clinical trials.
With regards to the discovery of biomarker, the concordance between PDX models and human trials allows us to discover biomarker for drug susceptibility and drug resistance. Furthermore, a relationship between drug efficacy and molecular (genetic) characteristics can be easily studied by using heterogeneous PDX models. For example, Sebastiani et al. [46] revealed relationship to molecular mechanism of gemcitabine resistance and survival in pancreatic cancer. PDX models are also valuable tools for generating drugresistant tumor models, which is achieved by repeated administration of a drug. Das Thakur et al. [47] generated vemurafenib-resistant melanoma model using PDX. They found elevated mutant BRAF protein by continuous drug treatment and this mutation is a critical factor for vemurafenib resistance. Likewise, proteomic or genetic comparison between sensitive and resistant models can be explored for the identification of prognostic biomarkers in clinical studies.

2) Co-clinical trial

The co-clinical trial denotes a clinical trial conducted in parallel with preclinical trial. The relevant clinical, biological, and pharmacologic information (i.e., somatic mutational background, germline single nucleotide polymorphism variations, responsiveness to specific regimens, imaging, microarray data, and proteomics profiles) are analyzed comprehensively, and integrated to identify biomarkers that predict a response to specific treatment [48-50]. In this approach, PDX model is developed from a patient enrolled in clinical trial and the PDX is treated with the same regimen to monitor clinical response [44]. By establishing PDXs of a patient enrolled in a clinical trial and treating it with a new agent, a screening for prognostic biomarkers can be performed and underlying drug response mechanisms can be studied. Based on this, novel combination strategies can be proposed. For example, Heid et al. [51] performed co-clinical assessment of tumor cellularity in pancreatic cancer. Owonikoko et al. [52] also reported that PDX faithfully replicated clinical outcome in a phase II co-clinical trial of arsenic trioxide in relapsed small cell lung cancer. Although it is not commonly tried so far, the co-clinical trial may be increased in the future because it can save time for drug development and reflects personalized medicine in a preclinical setting.

3) Precision medicine

Oncology research has evolved in parallel with the improved understanding of the cancer genotype and phenotype, leading to a new era of precision medicine [53]. This is colloquially termed “the right drug, for the right patient, at the right time.” In contrast to the conventional chemotherapy, the precision medicine combines individual patient’s characteristics, i.e., the genomic landscape of each tumor with molecularly targeted agents or immunotherapeutics to maximize treatment efficacy and minimize side effects [53]. Practically, the concept of precision medicine is to group patients into subpopulation based on sophisticated genomic profiling, enabling certain therapies to target the subgroup specifically [6]. Based on this notion, PDX is an appropriate model as it retains the genomic characters of individual tumor and represents a subgroup with similar genetic profile. Moreover, PDX model can even recapitulate heterogeneity within the same tumor specimen (intratumoral heterogeneity).
For example, a recent report showed integrated PDX models delineate individualized therapeutic vulnerabilities of pancreatic cancer [54]. In this study, an exom sequencing of patient tumor revealed multiple conserved genetic alterations. Using the PDX model, they showed the effectiveness and selectivity of treatment responses to more than 500 single and combination drug regimens. In addition, a genomic information-driven treatment was performed in advanced breast cancer using targeted next-generation sequencing (NGS), array-based comparative genomic hybridization data obtained from PDX model [55]. In ovarian cancer, anti-cancer drugs were tested for precision medicine approach, using PDX model [56]. Also, fine-tuning PDX model for precision medicine was tried in consideration of cross-species cytokine in leukemia [57]. Collectively, the efforts to implement personalized medicine using PDX model (summarized in Fig. 2) has been made in various cancers and enormous data would be accumulated with the progress of NGS and bioinformatic techniques [3].
Although PDX model is relatively easy and ideal model to research the cancer, there are limitations and challenges that need to be overcome. Firstly, the most appropriate tissue should be transplanted into mouse. In the case when a tumor size is very large, the part that can represent the tumor should be used for PDX. In this step, the help of pathologist and surgeon would be needed. Moreover, the tissue should be as fresh as possible, to generate PDX efficiently. Sometimes, smaller sample, such as fine-needle aspirations, are required to be transplanted for personalized medicine application. Therefore, the PDX technique using small specimen should be more studied and developed. Secondly, it is important to define the best strategy of engraftment in mice for different tumor type. Orthotopic implantation is considered more ideal, but special surgical technique is required depending on the cancer type and this way takes much time and effort for development. Subcutaneous implantation has relatively higher success rate and simpler procedure, so this approach is useful when lots of mouse needed to be grafted in the short time. Thirdly, duration of survival and treatment schedules for patients is also a considerable factor for personalized medicine applications. It normally takes 2-8 months to develop a PDX model for a preclinical study. In many cases, however, this length of time is too long for patients to wait. Fourthly, we need to deal with engraftment failure that is still high for some tumor types, such as hormone receptor–positive human breast cancer. Fifthly, a key aspect in PDX research is the use of immunodeficient mouse strain for tumor engraftment and propagation because mouse should avoid rejection of human tissue. For this reason, conventional PDX model is not appropriate for the screening of immune-modulating agents, such as vaccines and checkpoint blocking antibodies that function by activating host immune system. Instead, a humanized PDX model that has been transplanted human hematopoietic stem cells (CD34+ cells) [58] can be an alternative option. Sixthly, the replacement of human stromal components (such as cancerassociated fibroblasts, endothelial cells, immune and inflammatory cells) by murine elements could happen with repeated passages [59]. In this regard, the PDX has limit to mimic totally exact tumor microenvironment of human cancer and needs to find the way to overcome it.
Lastly, financial aspect cannot be ignored. It needs a substantial cost to develop PDX model because the immunodeficient mice are expensive and it takes long time to develop tumor. Nevertheless, the PDX is still considered as a worthy preclinical tool because of its uniqueness and many advantages as mentioned above.
As described in this review, the PDX model retains tumor characteristics such as cell-cell interactions and tumor microenvironment, although with some limitations. It is becoming clear that this model has many advantages in preclinical tests of drug screening, biomarker development and co-clinical trial. With the advances of NGS and other omics technique, we are approaching to obtain a comprehensive molecular signature for each patient’s tumor. We believe the PDX model is one of the appropriate preclinical tools to widen the personalized medicine strategy in the future. More studies for improving graft success rate as well as generating humanized PDX with the patients’ immune cells will accelerate the usage of this preclinical model.

Conflict of interest relevant to this article was not reported.

Acknowledgements
This work is supported by a grant of the Basic Science Research Program through a grant from Asan Institute for Life Sciences, Asan Medical Center (No. 2017-571) and a grant of Korean Health Technology R&D Project, Ministry of Health & Welfare, Republic of Korea (Grant Number: H14C2640).
Fig. 1.
An overall procedure for the generation of patient-derived xenograft (PDX) model. The PDX model can be developed by the implantation of fragments from a patient’s tumor into an immunodeficient mouse directly. A part of tumor from surgery (breast or pancreatic tumor in this example) is put in preserving media and the tumor is sliced into small fragments. The fragments are implanted subcutaneously or into the orthotopical organ, for example, mammary fat pad in the case of breast cancer.
crt-2017-307f1.gif
Fig. 2.
A flowchart showing the establishment of personalized medicine using patient-derived xenograft (PDX) model. Genomic signature of a primary tumor is analyzed by next-generation sequencing. At the same time, tumor fragments are implanted into immunodeficient mouse. The patient will be treated with the drug that showed best response in PDX. Also, a database of integrated genomic signature would be established to predict a drug response for a new patient with similar genomic signature. SNP, single nucleotide polymorphism.
crt-2017-307f2.gif
Table 1.
Summary of advantages/disadvantages of immune-deficient mouse strains for PDX
Mouse strain Deficiency Median survival Advantage Disadvantage
Nude No functional T cell Not determined Well characterized Functional B and NK cell
High take-rate of human tumor T-cell functionality increases with age
Not suitable for primary cell transplantation
SCID No functional T and B cell Not determined Better engrafment of allogeneic and xenogeneic tumor cells and tissues than in nude strain Functional NK cells
Spontaneous lymphomas
NOD-SCID No functional T and B cell 36 wk Low NK cell activity High incidence of lymphomas
NK cell impaired Very low leakiness with age Radiosensitive
Engrafts hematopoietic cancer cell line
NSG No functional T, B, and NK cell > 89 wk Lymphoma-resistant excellent engraftment of allogeneic and xenogeneic tumor cells and tissue Not well charaterized
Suitable for analysis of human cancer stem cells and metastasis

PDX, patient-derived xenograft; NK, natural killer; SCID, severely compromised immune deficient; NOD, nonobese diabetic; NSG, NOD-SCID mice with IL-2Rnull.

Table 2.
Success rate of PDX for various type of cancers grafted on different sites and strains
Tumor type Available model Mice strain Implantation site Engraftment rate (%) Reference
Colorectal cancer 130 NOD/SCID s.c. 87 [18]
Colorectal cancer 54 Nude s.c. 64 [19]
Colorectal cancer 41 Nude Orthotopic 89 [20]
Breast cancer 25 Nude s.c. 13 [21]
Breast cancer 12 NOD/SCID with estrogen supplementation for ER+ tumors Mammary fat pad 27 [22]
NSCLC 25 NOD/SCID s.c. 25 [23]
NSCLC 32 NOD/SCID Renal capsule 90 [24]
Pancreatic ductal carcinoma 42 Nude s.c. 61 [25]
Pancreatic ductal carcinoma 16 Nude Orthotopic 62 [26]
SCCHN 22 NSG s.c. 85 [27]
SCCHN/SCC 21 Nude s.c. 54 [28]
Uveal melanoma 25 NOD/SCID s.c. 28 [29]
Gastric cancer 15 Nude and NOG s.c. 24 [30]
Ovarian cancer 29 NSG i.p. 31 [31]
Prostate cancer 31 NOD/SCID Subrenal capsule 95 [32]
Renal cell carcinoma 30 Nude s.c. 8.9 [33]

PDX, patient-derived xenograft; NOD, nonobese diabetic; SCID, severely compromised immune deficient; s.c., subcutaneous; ER, estrogen receptor; NSCLC, non-small cell lung cancer; SCCHN, squamous cell carcinoma of the head and neck; NSG, NOD-SCID mice with IL-2Rnull; SCC, squamous cell carcinoma; NOG, NOD-SCID mice with c null; i.p., intraperitoneal.

  • 1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–86. ArticlePubMed
  • 2. Torre LA, Siegel RL, Ward EM, Jemal A. Global cancer incidence and mortality rates and trends: an update. Cancer Epidemiol Biomarkers Prev. 2016;25:16–27. ArticlePubMed
  • 3. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012;483:603–7. ArticlePubMedPMC
  • 4. van Weerden WM, Romijn JC. Use of nude mouse xenograft models in prostate cancer research. Prostate. 2000;43:263–71. ArticlePubMed
  • 5. DiMasi JA, Reichert JM, Feldman L, Malins A. Clinical approval success rates for investigational cancer drugs. Clin Pharmacol Ther. 2013;94:329–35. ArticlePubMed
  • 6. Cho SY, Kang W, Han JY, Min S, Kang J, Lee A, et al. An integrative approach to precision cancer medicine using patientderived xenografts. Mol Cells. 2016;39:77–86. ArticlePubMedPMCPDF
  • 7. Jung J, Lee CH, Seol HS, Choi YS, Kim E, Lee EJ, et al. Generation and molecular characterization of pancreatic cancer patient-derived xenografts reveals their heterologous nature. Oncotarget. 2016;7:62533–46. ArticlePubMedPMC
  • 8. Calles A, Rubio-Viqueira B, Hidalgo M. Primary human nonsmall cell lung and pancreatic tumorgraft models: utility and applications in drug discovery and tumor biology. Curr Protoc Pharmacol. 2013;Chapter 14:Unit 14.26.ArticlePubMedPDF
  • 9. Siolas D, Hannon GJ. Patient-derived tumor xenografts: transforming clinical samples into mouse models. Cancer Res. 2013;73:5315–9. ArticlePubMedPMC
  • 10. Morton CL, Houghton PJ. Establishment of human tumor xenografts in immunodeficient mice. Nat Protoc. 2007;2:247–50. ArticlePubMed
  • 11. Cao X, Shores EW, Hu-Li J, Anver MR, Kelsall BL, Russell SM, et al. Defective lymphoid development in mice lacking expression of the common cytokine receptor gamma chain. Immunity. 1995;2:223–38. ArticlePubMed
  • 12. Shultz LD, Lyons BL, Burzenski LM, Gott B, Chen X, Chaleff S, et al. Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells. J Immunol. 2005;174:6477–89. ArticlePubMed
  • 13. Greiner DL, Hesselton RA, Shultz LD. SCID mouse models of human stem cell engraftment. Stem Cells. 1998;16:166–77. ArticlePubMed
  • 14. Williams SA, Anderson WC, Santaguida MT, Dylla SJ. Patientderived xenografts, the cancer stem cell paradigm, and cancer pathobiology in the 21st century. Lab Invest. 2013;93:970–82. ArticlePubMed
  • 15. Zvibel I, Smets F, Soriano H. Anoikis: roadblock to cell transplantation? Cell Transplant. 2002;11:621–30. ArticlePubMed
  • 16. Jin K, Teng L, Shen Y, He K, Xu Z, Li G. Patient-derived human tumour tissue xenografts in immunodeficient mice: a systematic review. Clin Transl Oncol. 2010;12:473–80. ArticlePubMed
  • 17. Tentler JJ, Tan AC, Weekes CD, Jimeno A, Leong S, Pitts TM, et al. Patient-derived tumour xenografts as models for oncology drug development. Nat Rev Clin Oncol. 2012;9:338–50. ArticlePubMedPMC
  • 18. Bertotti A, Migliardi G, Galimi F, Sassi F, Torti D, Isella C, et al. A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Discov. 2011;1:508–23. ArticlePubMed
  • 19. Julien S, Merino-Trigo A, Lacroix L, Pocard M, Goere D, Mariani P, et al. Characterization of a large panel of patientderived tumor xenografts representing the clinical heterogeneity of human colorectal cancer. Clin Cancer Res. 2012;18:5314–28. ArticlePubMed
  • 20. Aytes A, Mollevi DG, Martinez-Iniesta M, Nadal M, Vidal A, Morales A, et al. Stromal interaction molecule 2 (STIM2) is frequently overexpressed in colorectal tumors and confers a tumor cell growth suppressor phenotype. Mol Carcinog. 2012;51:746–53. ArticlePubMed
  • 21. Marangoni E, Vincent-Salomon A, Auger N, Degeorges A, Assayag F, de Cremoux P, et al. A new model of patient tumor-derived breast cancer xenografts for preclinical assays. Clin Cancer Res. 2007;13:3989–98. ArticlePubMed
  • 22. DeRose YS, Wang G, Lin YC, Bernard PS, Buys SS, Ebbert MT, et al. Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes. Nat Med. 2011;17:1514–20. ArticlePubMedPMC
  • 23. Fichtner I, Rolff J, Soong R, Hoffmann J, Hammer S, Sommer A, et al. Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers. Clin Cancer Res. 2008;14:6456–68. ArticlePubMed
  • 24. Li S, Shen D, Shao J, Crowder R, Liu W, Prat A, et al. Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts. Cell Rep. 2013;4:1116–30. ArticlePubMedPMC
  • 25. Garrido-Laguna I, Uson M, Rajeshkumar NV, Tan AC, de Oliveira E, Karikari C, et al. Tumor engraftment in nude mice and enrichment in stroma-related gene pathways predict poor survival and resistance to gemcitabine in patients with pancreatic cancer. Clin Cancer Res. 2011;17:5793–800. ArticlePubMedPMC
  • 26. Reyes G, Villanueva A, Garcia C, Sancho FJ, Piulats J, Lluis F, et al. Orthotopic xenografts of human pancreatic carcinomas acquire genetic aberrations during dissemination in nude mice. Cancer Res. 1996;56:5713–9. PubMed
  • 27. Kimple RJ, Harari PM, Torres AD, Yang RZ, Soriano BJ, Yu M, et al. Development and characterization of HPV-positive and HPV-negative head and neck squamous cell carcinoma tumorgrafts. Clin Cancer Res. 2013;19:855–64. ArticlePubMedPMC
  • 28. Keysar SB, Astling DP, Anderson RT, Vogler BW, Bowles DW, Morton JJ, et al. A patient tumor transplant model of squamous cell cancer identifies PI3K inhibitors as candidate therapeutics in defined molecular bins. Mol Oncol. 2013;7:776–90. ArticlePubMedPMC
  • 29. Nemati F, Sastre-Garau X, Laurent C, Couturier J, Mariani P, Desjardins L, et al. Establishment and characterization of a panel of human uveal melanoma xenografts derived from primary and/or metastatic tumors. Clin Cancer Res. 2010;16:2352–62. ArticlePubMed
  • 30. Choi YY, Lee JE, Kim H, Sim MH, Kim KK, Lee G, et al. Establishment and characterisation of patient-derived xenografts as paraclinical models for gastric cancer. Sci Rep. 2016;6:22172.ArticlePubMedPMCPDF
  • 31. Boone JD, Dobbin ZC, Straughn JM Jr, Buchsbaum DJ. Ovarian and cervical cancer patient derived xenografts: The past, present, and future. Gynecol Oncol. 2015;138:486–91. ArticlePubMed
  • 32. Sun HB, Wang H, Taylor RA, Risbridger GP. Establishment of a xenograft model of human prostate cancer in mouse. Zhonghua Yi Xue Za Zhi. 2010;90:2136–9. PubMed
  • 33. Jimenez-Valerio G, Martinez-Lozano M, Bassani N, Vidal A, Ochoa-de-Olza M, Suarez C, et al. Resistance to antiangiogenic therapies by metabolic symbiosis in renal cell carcinoma PDX models and patients. Cell Rep. 2016;15:1134–43. ArticlePubMedPMC
  • 34. Marangoni E, Poupon MF. Patient-derived tumour xenografts as models for breast cancer drug development. Curr Opin Oncol. 2014;26:556–61. ArticlePubMed
  • 35. Cutz JC, Guan J, Bayani J, Yoshimoto M, Xue H, Sutcliffe M, et al. Establishment in severe combined immunodeficiency mice of subrenal capsule xenografts and transplantable tumor lines from a variety of primary human lung cancers: potential models for studying tumor progression-related changes. Clin Cancer Res. 2006;12:4043–54. ArticlePubMed
  • 36. Daniel VC, Marchionni L, Hierman JS, Rhodes JT, Devereux WL, Rudin CM, et al. A primary xenograft model of small-cell lung cancer reveals irreversible changes in gene expression imposed by culture in vitro. Cancer Res. 2009;69:3364–73. ArticlePubMedPMC
  • 37. Hutchinson L, Kirk R. High drug attrition rates: where are we going wrong? Nat Rev Clin Oncol. 2011;8:189–90. ArticlePubMed
  • 38. Malaney P, Nicosia SV, Dave V. One mouse, one patient paradigm: new avatars of personalized cancer therapy. Cancer Lett. 2014;344:1–12. ArticlePubMedPMC
  • 39. Reyal F, Guyader C, Decraene C, Lucchesi C, Auger N, Assayag F, et al. Molecular profiling of patient-derived breast cancer xenografts. Breast Cancer Res. 2012;14:R11.ArticlePubMedPMCPDF
  • 40. Richmond A, Su Y. Mouse xenograft models vs GEM models for human cancer therapeutics. Dis Model Mech. 2008;1:78–82. ArticlePubMedPMC
  • 41. Kerbel RS. Human tumor xenografts as predictive preclinical models for anticancer drug activity in humans: better than commonly perceived-but they can be improved. Cancer Biol Ther. 2003;2(4 Suppl 1):S134–9. ArticlePubMed
  • 42. Sivanand S, Pena-Llopis S, Zhao H, Kucejova B, Spence P, Pavia-Jimenez A, et al. A validated tumorgraft model reveals activity of dovitinib against renal cell carcinoma. Sci Transl Med. 2012;4:137ra75.ArticlePubMedPMC
  • 43. Migliardi G, Sassi F, Torti D, Galimi F, Zanella ER, Buscarino M, et al. Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patientderived xenografts of RAS-mutant colorectal carcinomas. Clin Cancer Res. 2012;18:2515–25. ArticlePubMed
  • 44. Hidalgo M, Amant F, Biankin AV, Budinska E, Byrne AT, Caldas C, et al. Patient-derived xenograft models: an emerging platform for translational cancer research. Cancer Discov. 2014;4:998–1013. ArticlePubMedPMC
  • 45. Lipner MB, Marayati R, Deng Y, Wang X, Raftery L, O'Neil BH, et al. Metformin treatment does not inhibit growth of pancreatic cancer patient-derived xenografts. PLoS One. 2016;11:e0147113ArticlePubMedPMC
  • 46. Sebastiani V, Ricci F, Rubio-Viqueira B, Kulesza P, Yeo CJ, Hidalgo M, et al. Immunohistochemical and genetic evaluation of deoxycytidine kinase in pancreatic cancer: relationship to molecular mechanisms of gemcitabine resistance and survival. Clin Cancer Res. 2006;12:2492–7. ArticlePubMedPMC
  • 47. Das Thakur M, Salangsang F, Landman AS, Sellers WR, Pryer NK, Levesque MP, et al. Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. Nature. 2013;494:251–5. ArticlePubMedPMC
  • 48. Garrido-Laguna I, Tan AC, Uson M, Angenendt M, Ma WW, Villaroel MC, et al. Integrated preclinical and clinical development of mTOR inhibitors in pancreatic cancer. Br J Cancer. 2010;103:649–55. ArticlePubMedPMC
  • 49. Jimeno A, Amador ML, Kulesza P, Wang X, Rubio-Viqueira B, Zhang X, et al. Assessment of celecoxib pharmacodynamics in pancreatic cancer. Mol Cancer Ther. 2006;5:3240–7. ArticlePubMed
  • 50. Nardella C, Lunardi A, Patnaik A, Cantley LC, Pandolfi PP. The APL paradigm and the "co-clinical trial" project. Cancer Discov. 2011;1:108–16. ArticlePubMedPMC
  • 51. Heid I, Steiger K, Trajkovic-Arsic M, Settles M, Esswein MR, Erkan M, et al. Co-clinical assessment of tumor cellularity in pancreatic cancer. Clin Cancer Res. 2017;23:1461–70. ArticlePubMed
  • 52. Owonikoko TK, Zhang G, Kim HS, Stinson RM, Bechara R, Zhang C, et al. Patient-derived xenografts faithfully replicated clinical outcome in a phase II co-clinical trial of arsenic trioxide in relapsed small cell lung cancer. J Transl Med. 2016;14:111.ArticlePubMedPMC
  • 53. Collins DC, Sundar R, Lim JS, Yap TA. Towards precision medicine in the clinic: from biomarker discovery to novel therapeutics. Trends Pharmacol Sci. 2017;38:25–40. ArticlePubMed
  • 54. Witkiewicz AK, Balaji U, Eslinger C, McMillan E, Conway W, Posner B, et al. Integrated patient-derived models delineate individualized therapeutic vulnerabilities of pancreatic cancer. Cell Rep. 2016;16:2017–31. ArticlePubMedPMC
  • 55. Goncalves A, Bertucci F, Guille A, Garnier S, Adelaide J, Carbuccia N, et al. Targeted NGS, array-CGH, and patientderived tumor xenografts for precision medicine in advanced breast cancer: a single-center prospective study. Oncotarget. 2016;7:79428–41. ArticlePubMedPMC
  • 56. Erriquez J, Olivero M, Mittica G, Scalzo MS, Vaira M, De Simone M, et al. Xenopatients show the need for precision medicine approach to chemotherapy in ovarian cancer. Oncotarget. 2016;7:26181–91. ArticlePubMedPMC
  • 57. Francis OL, Milford TA, Beldiman C, Payne KJ. Fine-tuning patient-derived xenograft models for precision medicine approaches in leukemia. J Investig Med. 2016;64:740–4. ArticlePubMedPMC
  • 58. Wiekmeijer AS, Pike-Overzet K, Brugman MH, Salvatori DC, Egeler RM, Bredius RG, et al. Sustained engraftment of cryopreserved human bone marrow CD34(+) cells in young adult NSG mice. Biores Open Access. 2014;3:110–6. ArticlePubMedPMC
  • 59. Lai Y, Wei X, Lin S, Qin L, Cheng L, Li P. Current status and perspectives of patient-derived xenograft models in cancer research. J Hematol Oncol. 2017;10:106.ArticlePubMedPMCPDF

Figure & Data

REFERENCES

    Citations

    Citations to this article as recorded by  
    • Microfluidic Organoid Cultures Derived from Pancreatic Cancer Biopsies for Personalized Testing of Chemotherapy and Immunotherapy
      Daheui Choi, Alan M. Gonzalez‐Suarez, Mihai G. Dumbrava, Michael Medlyn, Jose M. de Hoyos‐Vega, Frank Cichocki, Jeffrey S. Miller, Li Ding, Mojun Zhu, Gulnaz Stybayeva, Alexandre Gaspar‐Maia, Daniel D. Billadeau, Wen Wee Ma, Alexander Revzin
      Advanced Science.2024;[Epub]     CrossRef
    • Statistical classification of treatment responses in mouse clinical trials for stratified medicine in oncology drug discovery
      Hélène Savel, Florence Meyer-Losic, Cécile Proust-Lima, Laura Richert
      Scientific Reports.2024;[Epub]     CrossRef
    • Evaluation of chicken chorioallantoic membrane model for tumor imaging and drug development: Promising findings
      Lizhen Wang, Junjie Yan, XinyuWang, Yuping Xu, Donghui Pan, Chongyang Chen, Ying Shao, Xiangjun Song, Kezong Qi, Min Yang, Jian Tu
      Animal Models and Experimental Medicine.2024;[Epub]     CrossRef
    • Biomaterials for Drug Delivery and Human Applications
      Paolo Trucillo
      Materials.2024; 17(2): 456.     CrossRef
    • Transcriptomic, Proteomic, and Genomic Mutational Fraction Differences Based on HPV Status Observed in Patient-Derived Xenograft Models of Penile Squamous Cell Carcinoma
      Niki M. Zacharias, Luis Segarra, Keiko Akagi, Natalie Wall Fowlkes, Huiqin Chen, Angelita Alaniz, Carolyn de la Cerda, Pedro Pesquera, Yuanxin Xi, Jing Wang, Jad Chahoud, Xin Lu, Priya Rao, Magaly Martinez-Ferrer, Curtis A. Pettaway
      Cancers.2024; 16(5): 1066.     CrossRef
    • A Case Study of a Rare Undifferentiated Spindle Cell Sarcoma of the Penis: Establishment and Characterization of Patient-Derived Models
      Ariane Cavalcante dos Santos Sousa, Bruno Leonardo Nascimento Correa Fernandes, Jeronimo Paulo Assis da Silva, Paulo Roberto Stevanato Filho, Luiza Bitencourt de Carvalho Terci Coimbra, Adriano de Oliveira Beserra, Ana Luiza Alvarenga, Giovanna Maida, Cam
      Genes.2024; 15(4): 424.     CrossRef
    • Burning down the house: Pyroptosis in the tumor microenvironment of hepatocellular carcinoma
      Chi Cheng, Sheng-Kai Hsu, Yen-Chun Chen, Wangta Liu, En-De Shu, Ching-Ming Chien, Chien-Chih Chiu, Wen-Tsan Chang
      Life Sciences.2024; 347: 122627.     CrossRef
    • PDX Models in Theranostic Applications: Generation and Screening for B Cell Lymphoma of Human Origin
      Shayla Shmuel, Sébastien Monette, Dina Ibrahim, Patrícia M.R. Pereira
      Molecular Imaging and Biology.2024; 26(4): 569.     CrossRef
    • A review of animal models utilized in preclinical studies of approved gene therapy products: trends and insights
      Parham Soufizadeh, Vahid Mansouri, Naser Ahmadbeigi
      Laboratory Animal Research.2024;[Epub]     CrossRef
    • Applied models and molecular characteristics of small cell lung cancer
      Gabriella Mihalekné Fűr, Kolos Nemes, Éva Magó, Alexandra Á. Benő, Petronella Topolcsányi, Judit Moldvay, Lőrinc S. Pongor
      Pathology and Oncology Research.2024;[Epub]     CrossRef
    • Advances in the study of gastric organoids as disease models
      Yi-Yang Liu, De-Kun Wu, Ji-Bing Chen, You-Ming Tang, Feng Jiang
      World Journal of Gastrointestinal Oncology.2024; 16(5): 1725.     CrossRef
    • Cancer research revolutionized: Unveiling the power of organoids and their therapeutic potential in oncology
      Yingxin Zhang, Ming Liu, Na Xie, Zhoufeng Wang, Chuanjiang Yu, Jing Li, Xikun Zhou
      hLife.2024;[Epub]     CrossRef
    • The potential of organoids in renal cell carcinoma research
      Qiuyang Chen, Xuan Sun, Yubei Li, Xinyue Yang, Xuejian Yang, Haifei Xu, Hongzhou Cai, Jun Hu
      BMC Urology.2024;[Epub]     CrossRef
    • Zebrafish Xenographs in Oncology and Personalized Medicine
      N. A. Lunina, D. R. Safina, S. V. Kostrov
      Molecular Biology.2024; 58(3): 381.     CrossRef
    • Revolutionizing digestive system tumor organoids research: Exploring the potential of tumor organoids
      Zhian Xiu, Qian Yang, Fusheng Xie, Feng Han, Weiwei He, Weifang Liao
      Journal of Tissue Engineering.2024;[Epub]     CrossRef
    • Prodrug-inspired adenosine triphosphate–activatable celastrol-Fe(III) chelate for cancer therapy
      Hanrong Li, Yifan Li, Lingpu Zhang, Nan Wang, Dong Lu, Dongsheng Tang, Yitong Lv, Jinbo Zhang, Heben Yan, He Gong, Ming Zhang, Kaili Nie, Yi Hou, Yingjie Yu, Haihua Xiao, Chaoyong Liu
      Science Advances.2024;[Epub]     CrossRef
    • Reversion of pathogenic BRCA1 L1780P mutation confers resistance to PARP and ATM inhibitor in breast cancer
      Se-Young Jo, Jeong Dong Lee, Jeongsoo Won, Jiho Park, Taeyong Kweon, Seongyeon Jo, Joohyuk Sohn, Seung-Il Kim, Sangwoo Kim, Hyung Seok Park
      iScience.2024; 27(8): 110469.     CrossRef
    • Preclinical Models of Hepatocellular Carcinoma: Current Utility, Limitations, and Challenges
      Antonio Cigliano, Weiting Liao, Giovanni A. Deiana, Davide Rizzo, Xin Chen, Diego F. Calvisi
      Biomedicines.2024; 12(7): 1624.     CrossRef
    • Recent advances in lung cancer organoid (tumoroid) research (Review)
      Qiang Zhang, Mingyang Zhang
      Experimental and Therapeutic Medicine.2024;[Epub]     CrossRef
    • Cannabinoid combination targets NOTCH1-mutated T-cell acute lymphoblastic leukemia through the integrated stress response pathway
      Elazar Besser, Anat Gelfand, Shiri Procaccia, Paula Berman, David Meiri
      eLife.2024;[Epub]     CrossRef
    • Radiobiological Applications of Vibrational Spectroscopy: A Review of Analyses of Ionising Radiation Effects in Biology and Medicine
      Jade F. Monaghan, Hugh J. Byrne, Fiona M. Lyng, Aidan D. Meade
      Radiation.2024; 4(3): 276.     CrossRef
    • The roles of patient‐derived xenograft models and artificial intelligence toward precision medicine
      Venkatachalababu Janitri, Kandasamy Nagarajan ArulJothi, Vijay Murali Ravi Mythili, Sachin Kumar Singh, Parteek Prasher, Gaurav Gupta, Kamal Dua, Rakshith Hanumanthappa, Karthikeyan Kaliappan, Krishnan Anand
      MedComm.2024;[Epub]     CrossRef
    • Unveiling the Therapeutic Potential of Paclitaxel Combinations Against Breast Carcinoma and Identification of In Vivo Biomarkers
      Aamir Mehmood, Mohd Sajid Ali, Daixi Li, Aman Chandra Kaushik, Dong‐Qing Wei
      Chemical Biology & Drug Design.2024;[Epub]     CrossRef
    • Mimicking and analyzing the tumor microenvironment
      Roxane Crouigneau, Yan-Fang Li, Jamie Auxillos, Eliana Goncalves-Alves, Rodolphe Marie, Albin Sandelin, Stine Falsig Pedersen
      Cell Reports Methods.2024; 4(10): 100866.     CrossRef
    • Telaglenastat as an alternative to cisplatin as a radiosensitizer in the treatment of head and neck squamous cell carcinoma
      Julianna Korns, Christina A. Wicker, Maria Lehn, Shreya Shyamsunder, Samuel Thompson, Carissa Lester, Trisha M. Wise-Draper, Susan E. Waltz, Vinita Takiar
      Cancer Letters.2024; 606: 217320.     CrossRef
    • Engineering liquid metal-based nanozyme for enhancing microwave dynamic therapy in breast cancer PDX model
      Qiong Wu, Yongnian Yu, Xiaorui Yu, Qijun Du, Li Gou, Longfei Tan, Changhui Fu, Xiangling Ren, Jun Ren, Kai Xiao, Xianwei Meng
      Journal of Nanobiotechnology.2023;[Epub]     CrossRef
    • An integrated PK/PD model investigating the impact of tumor size and systemic safety on animal survival in SW1990 pancreatic cancer xenograft
      Qing-yu Yao, Jun Zhou, Ye Yao, Jun-sheng Xue, Yu-chen Guo, Wei-zhe Jian, Ren-wei Zhang, Xiao-yan Qiu, Tian-yan Zhou
      Acta Pharmacologica Sinica.2023; 44(2): 465.     CrossRef
    • Opportunities for pharmacoproteomics in biomarker discovery
      Rebecca C. Poulos, Zhaoxiang Cai, Phillip J. Robinson, Roger R. Reddel, Qing Zhong
      PROTEOMICS.2023;[Epub]     CrossRef
    • Hydrogel Microtumor Arrays to Evaluate Nanotherapeutics
      Yiling Liu, Stephanie Nemec, Chantal Kopecky, Martina H. Stenzel, Kristopher A. Kilian
      Advanced Healthcare Materials.2023;[Epub]     CrossRef
    • Patient‐derived xenograft model in colorectal cancer basic and translational research
      Xiaofeng Liu, Zechang Xin, Kun Wang
      Animal Models and Experimental Medicine.2023; 6(1): 26.     CrossRef
    • AKR1C2 Promotes Metastasis and Regulates the Molecular Features of Luminal Androgen Receptor Subtype in Triple Negative Breast Cancer Cells
      Songbin Li, Woochan Lee, Woohang Heo, Hye-Youn Son, Yujeong Her, Jong-Il Kim, Hyeong-Gon Moon
      Journal of Breast Cancer.2023; 26(1): 60.     CrossRef
    • Spotlight on P2X7 Receptor PET Imaging: A Bright Target or a Failing Star?
      Stephan Schmidt, Andreas Isaak, Anna Junker
      International Journal of Molecular Sciences.2023; 24(2): 1374.     CrossRef
    • Using patient-derived organoids to predict locally advanced or metastatic lung cancer tumor response: A real-world study
      Han-Min Wang, Chan-Yuan Zhang, Kai-Cheng Peng, Ze-Xin Chen, Jun-Wei Su, Yu-Fa Li, Wen-Feng Li, Qing-Yun Gao, Shi-Ling Zhang, Yu-Qing Chen, Qing Zhou, Cong Xu, Chong-Rui Xu, Zhen Wang, Jian Su, Hong-Hong Yan, Xu-Chao Zhang, Hua-Jun Chen, Yi-Long Wu, Jin-Ji
      Cell Reports Medicine.2023; 4(2): 100911.     CrossRef
    • On the Choice of Longitudinal Models for the Analysis of Antitumor Efficacy in Mouse Clinical Trials of Patient-derived Xenograft Models
      Hélène Savel, Sandrine Barbier, Cécile Proust-Lima, Virginie Rondeau, Rodolphe Thiébaut, Florence Meyer-Losic, Laura Richert
      Cancer Research Communications.2023; 3(1): 140.     CrossRef
    • Development and characterization of patient-derived xenograft models of colorectal cancer for testing new pharmacological substances
      A. S. Goncharova, E. N. Kolesnikov, G. Yu. Egorov, A. Yu. Maksimov, A. N. Shevchenko, E. M. Nepomnyashchaya, D. Yu. Gvaldin, L. Z. Kurbanova, D. V. Khodakova, S. O. Kit, O. Yu. Kaymakchi, A. V. Snezhko
      Bulletin of Siberian Medicine.2023; 21(4): 37.     CrossRef
    • Selinexor demonstrates anti-tumor efficacy in paired patient-derived xenograft models and hydrogel-embedded histoculture drug sensitivity test of penile cancer
      Yuanqiao He, Jiaqi Mei, Hua Hao, Fanrong Liu, Yun Yi, Chao Hu, Fangxing Zou, Xiongbing Lu
      Journal of Cancer Research and Clinical Oncology.2023; 149(10): 6931.     CrossRef
    • Potential roles of lncRNA-XIST/miRNAs/mRNAs in human cancer cells
      Maryam Farzaneh, Ava Nasrolahi, Farhoodeh Ghaedrahmati, Tariq Masoodi, Sajad Najafi, Mohadeseh Sheykhi-Sabzehpoush, Mahrokh Abouali Gale Dari, Klaudia Radoszkiewicz, Shahab Uddin, Shirin Azizidoost, Seyed Esmaeil Khoshnam
      Clinical and Translational Oncology.2023; 25(7): 2015.     CrossRef
    • Experimental mouse models for translational human cancer research
      Yinxi Zhou, Jinghua Xia, Shuonan Xu, Tao She, Yanning Zhang, Ying Sun, Miaomiao Wen, Tao Jiang, Yanlu Xiong, Jie Lei
      Frontiers in Immunology.2023;[Epub]     CrossRef
    • A novel method to identify and characterize personalized functional driver lncRNAs in cancer samples
      Xuan Zheng, Feng Li, Hongying Zhao, Yongjuan Tang, Ke Xue, Xiaomeng Zhang, Weixin Liang, Rui Zhao, Xingyu Lv, Xinyu Song, Chunlong Zhang, Yanjun Xu, Yunpeng Zhang
      Computational and Structural Biotechnology Journal.2023; 21: 2471.     CrossRef
    • Patient‐derived xenograft mouse models to investigate tropism to the central nervous system and retina of primary and secondary central nervous system lymphoma
      Lisa Kristina Isbell, Cordula Tschuch, Soroush Doostkam, Silvia Waldeck, Geoffroy Andrieux, Khalid Shoumariyeh, Dorothee Lenhard, Hans Eckart Schaefer, Peter Christoph Reinacher, Ingrid Bartsch, Milena Pantic, Janaki Manoja Vinnakota, Vinodh Kakkassery, E
      Neuropathology and Applied Neurobiology.2023;[Epub]     CrossRef
    • Towards an optimal model for gastric cancer peritoneal metastasis: current challenges and future directions
      Zehui Li, Jin Wang, Zhenning Wang, Yan Xu
      eBioMedicine.2023; 92: 104601.     CrossRef
    • Effects of Mouse Kidney Parvovirus on Pharmacokinetics of Chemotherapeutics and the Adenine Model of Chronic Kidney Disease
      Amanda C Ritter, Rodolfo Ricart J Arbona, Robert S Livingston, Sébastien Monette, Neil S Lipman
      Comparative Medicine.2023; 73(2): 153.     CrossRef
    • Alteration in molecular properties during establishment and passaging of endometrial carcinoma patient-derived xenografts
      Toshio Imai, Hiroshi Yoshida, Yukino Machida, Mizuki Kuramochi, Hitoshi Ichikawa, Takashi Kubo, Mami Takahashi, Tomoyasu Kato
      Scientific Reports.2023;[Epub]     CrossRef
    • Exploratory study on the efficacy of bortezomib combining mitoxantrone or CD22-CAR T therapy targeting CD19-negative relapse after CD19-CAR T cell therapy with a simpler cell-line-based model
      Diandian Ba, Hongzhe Li, Rongrong Liu, Ping Zhang, Yongmin Tang
      Apoptosis.2023; 28(11-12): 1534.     CrossRef
    • Generation, evolution, interfering factors, applications, and challenges of patient-derived xenograft models in immunodeficient mice
      Mingtang Zeng, Zijing Ruan, Jiaxi Tang, Maozhu Liu, Chengji Hu, Ping Fan, Xinhua Dai
      Cancer Cell International.2023;[Epub]     CrossRef
    • Patient-derived tumor models: a suitable tool for preclinical studies on esophageal cancer
      Fan Liang, Hongyan Xu, Hongwei Cheng, Yabo Zhao, Junhe Zhang
      Cancer Gene Therapy.2023; 30(11): 1443.     CrossRef
    • Association of cyclooxygenase-2 expression with endoplasmic reticulum stress and autophagy in triple-negative breast cancer
      Haechan Lee, SungWook Jung, Gyungyub Gong, Bora Lim, Hee Jin Lee, Irina V. Lebedeva
      PLOS ONE.2023; 18(8): e0289627.     CrossRef
    • Development of a small cell lung cancer organoid model to study cellular interactions and survival after chemotherapy
      Chandani Sen, Caroline R. Koloff, Souvik Kundu, Dan C. Wilkinson, Juliette M. Yang, David W. Shia, Luisa K. Meneses, Tammy M. Rickabaugh, Brigitte N. Gomperts
      Frontiers in Pharmacology.2023;[Epub]     CrossRef
    • The challenge of making the right choice: patient avatars in the era of cancer immunotherapies
      Charlotte Kayser, Annika Brauer, Sebens Susanne, Anna Maxi Wandmacher
      Frontiers in Immunology.2023;[Epub]     CrossRef
    • Progress in construction of mouse models to investigate the pathogenesis and immune therapy of human hematological malignancy
      Yue Lang, Yanan Lyu, Yehui Tan, Zheng Hu
      Frontiers in Immunology.2023;[Epub]     CrossRef
    • Unlocking Translational Potential: Conditionally Reprogrammed Cells in Advancing Breast Cancer Research
      Danyal Daneshdoust, Mingjue Luo, Zaibo Li, Xiaokui Mo, Sahar Alothman, Bhaskar Kallakury, Richard Schlegel, Junran Zhang, Deliang Guo, Priscilla A. Furth, Xuefeng Liu, Jenny Li
      Cells.2023; 12(19): 2388.     CrossRef
    • Patient-derived tumor models in cancer research: Evaluation of the oncostatic effects of melatonin
      Laura Martinez-Ruiz, Alba López-Rodríguez, Javier Florido, Cesar Rodríguez-Santana, José M. Rodríguez Ferrer, Darío Acuña-Castroviejo, Germaine Escames
      Biomedicine & Pharmacotherapy.2023; 167: 115581.     CrossRef
    • Modeling Liver Development and Disease in a Dish
      Waqas Iqbal, Yaru Wang, Pingnan Sun, Xiaoling Zhou
      International Journal of Molecular Sciences.2023; 24(21): 15921.     CrossRef
    • BR55 Ultrasound Molecular Imaging of Clear Cell Renal Cell Carcinoma Reflects Tumor Vascular Expression of VEGFR-2 in a Patient-Derived Xenograft Model
      Jean Courcier, Ingrid Leguerney, Baya Benatsou, Sibylle Pochon, Isabelle Tardy, Laurence Albiges, Paul-Henry Cournède, Alexandre De La Taille, Nathalie Lassau, Alexandre Ingels
      International Journal of Molecular Sciences.2023; 24(22): 16211.     CrossRef
    • Patient Characteristics Associated with Growth of Patient-Derived Tumor Implants in Mice (Patient-Derived Xenografts)
      Tatiana Hernández Guerrero, Natalia Baños, Laura del Puerto Nevado, Ignacio Mahillo-Fernandez, Bernard Doger De-Speville, Emiliano Calvo, Michael Wick, Jesús García-Foncillas, Victor Moreno
      Cancers.2023; 15(22): 5402.     CrossRef
    • Comparative RNA-Seq Analysis Revealed Tissue-Specific Splicing Variations during the Generation of the PDX Model
      Eun Ji Lee, Seung-Jae Noh, Huiseon Choi, Min Woo Kim, Su Jin Kim, Yeon Ah Seo, Ji Eun Jeong, Inkyung Shin, Jong-Seok Kim, Jong-Kwon Choi, Dae-Yeon Cho, Suhwan Chang
      International Journal of Molecular Sciences.2023; 24(23): 17001.     CrossRef
    • PC Kz is the novel human prostate cancer model in vitro and in vivo
      Darina V. Sokolova, Irina I. Khan, Dmitry D. Zhdanov, Elena A. Demidova, Valery O. Krivchenko, Chingis Aidossov, Vadim S. Pokrovsky
      Russian Journal of Oncology.2023; 28(1): 37.     CrossRef
    • Predicting chemosensitivity based on mini patient-derived xenografts in osteosarcoma patients: A retrospective study
      Zuoyao Long, Yajie Lu, Minghui Li, Chuanlei Ji, Guojing Chen, Jing Li, Liangbi Xiang, Hailong Yu, Qi Wang, Zhen Wang
      Journal of Cancer Research and Therapeutics.2023; 19(1): 71.     CrossRef
    • A rapid and simple procedure for the isolation and cultivation of fibroblast-like cells from medaka and zebrafish embryos and fin clip biopsies
      Lars Beedgen, Andreas Hüllen, Sevinç Gücüm, Thomas Thumberger, Jochen Wittbrodt, Christian Thiel
      Laboratory Animals.2022; 56(3): 270.     CrossRef
    • Harnessing the predictive power of preclinical models for oncology drug development
      Alexander Honkala, Sanjay V. Malhotra, Shivaani Kummar, Melissa R. Junttila
      Nature Reviews Drug Discovery.2022; 21(2): 99.     CrossRef
    • The Cell‐Isolation Capsules with Rod‐Like Channels Ensure the Survival and Response of Cancer Cells to Their Microenvironment
      Lanlan Hui, Deng Wang, Zhao Liu, Yueqi Zhao, Zhongzhong Ji, Man Zhang, Helen He Zhu, Wenqing Luo, Xiaomu Cheng, Liming Gui, Wei‐Qiang Gao
      Advanced Healthcare Materials.2022;[Epub]     CrossRef
    • Des sphéroïdes aux organoïdes : modèles de cancers solides pour la découverte de molécules anticancéreuses
      George Alzeeb, Laurent Corcos, Catherine Le Jossic-Corcos
      Bulletin du Cancer.2022; 109(1): 49.     CrossRef
    • Inhibition of Musashi-1 enhances chemotherapeutic sensitivity in gastric cancer patient-derived xenografts
      Fan Liu, Huan Yang, Xinyu Zhang, Xianglin Sun, Jiamin Zhou, Yuan Li, Yifei Liu, Zhixiang Zhuang, Guohua Wang
      Experimental Biology and Medicine.2022; 247(10): 868.     CrossRef
    • Inhibition of growth of colorectal cancer patient-derived subcutaneous xenografts using combined Wnt signaling pathway inhibitor and 5‑fluorouracil
      A. S. Goncharova, A. V. Galina, D. V. Khodakova, G. Yu. Egorov, A. Yu. Maksimov, E. N. Kolesnikov, E. F. Komarova, A. A. Kiblitskaya, E. V. Zaikina, L. Z. Kurbanova, M. V. Mindar
      Research and Practical Medicine Journal.2022; 9(1): 33.     CrossRef
    • Chick Chorioallantoic Membrane (CAM) Assays as a Model of Patient-Derived Xenografts from Circulating Cancer Stem Cells (cCSCs) in Breast Cancer Patients
      Monika Pizon, Dorothea Schott, Ulrich Pachmann, Rainer Schobert, Marek Pizon, Marta Wozniak, Rafal Bobinski, Katharina Pachmann
      Cancers.2022; 14(6): 1476.     CrossRef
    • Applications of the Chick Chorioallantoic Membrane as an Alternative Model for Cancer Studies
      Pei-Yu Chu, Angele Pei-Fern Koh, Jane Antony, Ruby Yun-Ju Huang
      Cells Tissues Organs.2022; 211(2): 222.     CrossRef
    • Comparison of classical tumour growth models for patient derived and cell-line derived xenografts using the nonlinear mixed-effects framework
      Dimitrios Voulgarelis, Krishna C. Bulusu, James W. T. Yates
      Journal of Biological Dynamics.2022; 16(1): 160.     CrossRef
    • Three-dimensional models of the lung: past, present and future: a mini review
      Chandani Sen, Delilah Freund, Brigitte N. Gomperts
      Biochemical Society Transactions.2022; 50(2): 1045.     CrossRef
    • The Patient-Derived Cancer Organoids: Promises and Challenges as Platforms for Cancer Discovery
      JuneSung Bae, Yun Sik Choi, Gunsik Cho, Se Jin Jang
      Cancers.2022; 14(9): 2144.     CrossRef
    • Patient-derived xenograft (PDX) models, applications and challenges in cancer research
      Shahrokh Abdolahi, Zeinab Ghazvinian, Samad Muhammadnejad, Mahshid Saleh, Hamid Asadzadeh Aghdaei, Kaveh Baghaei
      Journal of Translational Medicine.2022;[Epub]     CrossRef
    • Patient-Derived Xenograft: A More Standard “Avatar” Model in Preclinical Studies of Gastric Cancer
      Mingtang Zeng, Chao Pi, Ke Li, Lin Sheng, Ying Zuo, Jiyuan Yuan, Yonggen Zou, Xiaomei Zhang, Wenmei Zhao, Robert J. Lee, Yumeng Wei, Ling Zhao
      Frontiers in Oncology.2022;[Epub]     CrossRef
    • Experimental approach to obtaining subcutaneous xenograft of non-small cell lung cancer
      E. A. Lukbanova, M. V. Mindar, E. A. Dzhenkova, A. Yu. Maksimov, A. S. Goncharova, Yu. S. Shatova, A. A. Maslov, A. V. Shaposhnikov, E. V. Zaikina, Yu. N. Lazutin
      Research and Practical Medicine Journal.2022; 9(2): 65.     CrossRef
    • Spontaneous xenogeneicGvHDin Wilms' tumorPatient‐Derivedxenograft models and potential solutions
      Seyed Mostafa Monzavi, Ahad Muhammadnejad, Maryam Behfar, Amir Arsalan Khorsand, Samad Muhammadnejad, Abdol‐Mohammad Kajbafzadeh
      Animal Models and Experimental Medicine.2022; 5(4): 389.     CrossRef
    • Mouse Models of Hepatocellular Carcinoma: Classification, Advancement, and Application
      Sha Liu, Fang Huang, Guoqing Ru, Yigang Wang, Bixiang Zhang, Xiaoping Chen, Liang Chu
      Frontiers in Oncology.2022;[Epub]     CrossRef
    • Recent advances in the development of transplanted colorectal cancer mouse models
      Yu-Shen Yang, Chu-Yun Liu, Dan Wen, Da-Zhi Gao, Shu Lin, He-fan He, Xue-Feng Zhao
      Translational Research.2022; 249: 128.     CrossRef
    • Antibody-mediated blockade for galectin-3 binding protein in tumor secretome abrogates PDAC metastasis
      Yeon-Sook Choi, Myung Ji Kim, Eun A. Choi, Sinae Kim, Eun ji Lee, Min Ji Park, Mi-Ju Kim, Yeon Wook Kim, Hee-Sung Ahn, Jae Yun Jung, Gayoung Jang, Yongsub Kim, Hyori Kim, Kyunggon Kim, Jin Young Kim, Seung-Mo Hong, Song Cheol Kim, Suhwan Chang
      Proceedings of the National Academy of Sciences.2022;[Epub]     CrossRef
    • CombPDX: a unified statistical framework for evaluating drug synergism in patient-derived xenografts
      Licai Huang, Jing Wang, Bingliang Fang, Funda Meric-Bernstam, Jack A. Roth, Min Jin Ha
      Scientific Reports.2022;[Epub]     CrossRef
    • HSSG: Identification of Cancer Subtypes Based on Heterogeneity Score of A Single Gene
      Shanchen Pang, Wenhao Wu, Yuanyuan Zhang, Shudong Wang, Muyuan Niu, Kuijie Zhang, Wenjing Yin
      Cells.2022; 11(15): 2456.     CrossRef
    • Zebrafish Models of Paediatric Brain Tumours
      Faiza Basheer, Poshmaal Dhar, Rasika M. Samarasinghe
      International Journal of Molecular Sciences.2022; 23(17): 9920.     CrossRef
    • Modelling metabolic diseases and drug response using stem cells and organoids
      Wenxiang Hu, Mitchell A. Lazar
      Nature Reviews Endocrinology.2022; 18(12): 744.     CrossRef
    • Multifunctional stimuli-responsive hybrid nanogels for cancer therapy: Current status and challenges
      Amaal Abdulraqeb Ali, Amani Al-Othman, Mohammad H. Al-Sayah
      Journal of Controlled Release.2022; 351: 476.     CrossRef
    • Predictive validity in drug discovery: what it is, why it matters and how to improve it
      Jack W. Scannell, James Bosley, John A. Hickman, Gerard R. Dawson, Hubert Truebel, Guilherme S. Ferreira, Duncan Richards, J. Mark Treherne
      Nature Reviews Drug Discovery.2022; 21(12): 915.     CrossRef
    • Variants of creating heterotopic and orthotopic PDX models of human colorectal cancer
      A. A. Kiblitskaya, A. Y. Maksimov, A. S. Goncharova, Ye. M. Nepomnyashchaya, Ye. Y. Zlatnik, G. Y. Yegorov, Ye. A. Lukbanova, Ye. V. Zaikina, A. V. Volkova
      Bulletin of Siberian Medicine.2022; 21(3): 50.     CrossRef
    • Multiparametric Magnetic Resonance Imaging and Metabolic Characterization of Patient-Derived Xenograft Models of Clear Cell Renal Cell Carcinoma
      Joao Piraquive Agudelo, Deepti Upadhyay, Dalin Zhang, Hongjuan Zhao, Rosalie Nolley, Jinny Sun, Shubhangi Agarwal, Robert A. Bok, Daniel B. Vigneron, James D. Brooks, John Kurhanewicz, Donna M. Peehl, Renuka Sriram
      Metabolites.2022; 12(11): 1117.     CrossRef
    • Patient-derived xenograft models for gastrointestinal tumors: A single-center retrospective study
      Xiongfei Yu, Yiran Chen, Jun Lu, Kuifeng He, Yanyan Chen, Yongfeng Ding, Ketao Jin, Haiyong Wang, Haibin Zhang, Haohao Wang, Lisong Teng
      Frontiers in Oncology.2022;[Epub]     CrossRef
    • Optimizing Drug Response Study Design in Patient-Derived Tumor Xenografts
      Jessica Weiss, Nhu-An Pham, Melania Pintilie, Ming Li, Geoffrey Liu, Frances A Shepherd, Ming-Sound Tsao, Wei Xu
      Cancer Informatics.2022;[Epub]     CrossRef
    • Current methods for studying metastatic potential of tumor cells
      Pavla Bouchalova, Pavel Bouchal
      Cancer Cell International.2022;[Epub]     CrossRef
    • Integrative Multi-OMICs Identifies Therapeutic Response Biomarkers and Confirms Fidelity of Clinically Annotated, Serially Passaged Patient-Derived Xenografts Established from Primary and Metastatic Pediatric and AYA Solid Tumors
      Pankita H. Pandya, Asha Jacob Jannu, Khadijeh Bijangi-Vishehsaraei, Erika Dobrota, Barbara J. Bailey, Farinaz Barghi, Harlan E. Shannon, Niknam Riyahi, Nur P. Damayanti, Courtney Young, Rada Malko, Ryli Justice, Eric Albright, George E. Sandusky, L. Danie
      Cancers.2022; 15(1): 259.     CrossRef
    • Antibody-drug conjugates: an evolving approach for melanoma treatment
      Trevor S. Anderson, Amanda L. Wooster, Ninh M. La-Beck, Dipongkor Saha, Devin B. Lowe
      Melanoma Research.2021; 31(1): 1.     CrossRef
    • Establishment and Long-Term Expansion of Small Cell Lung Cancer Patient-Derived Tumor Organoids
      Seon Young Choi, Yong-Hee Cho, Da-Som Kim, Wonjun Ji, Chang-Min Choi, Jae Cheol Lee, Jin Kyung Rho, Gi Seok Jeong
      International Journal of Molecular Sciences.2021; 22(3): 1349.     CrossRef
    • Enhanced anti-tumor efficacy of IL-7/CCL19-producing human CAR-T cells in orthotopic and patient-derived xenograft tumor models
      Shunsuke Goto, Yukimi Sakoda, Keishi Adachi, Yoshitaka Sekido, Seiji Yano, Masatoshi Eto, Koji Tamada
      Cancer Immunology, Immunotherapy.2021; 70(9): 2503.     CrossRef
    • PDX-Derived Ewing’s Sarcoma Cells Retain High Viability and Disease Phenotype in Alginate Encapsulated Spheroid Cultures
      Giacomo Domenici, Rodrigo Eduardo, Helena Castillo-Ecija, Gorka Orive, Ángel Montero Carcaboso, Catarina Brito
      Cancers.2021; 13(4): 879.     CrossRef
    • Using the Microwell-mesh to culture microtissues in vitro and as a carrier to implant microtissues in vivo into mice
      Melissa E. Monterosso, Kathryn Futrega, William B. Lott, Ian Vela, Elizabeth D. Williams, Michael R. Doran
      Scientific Reports.2021;[Epub]     CrossRef
    • The Chicken Chorioallantoic Membrane Tumor Assay as a Relevant In Vivo Model to Study the Impact of Hypoxia on Tumor Progression and Metastasis
      Kelly Harper, Anna Yatsyna, Martine Charbonneau, Karine Brochu-Gaudreau, Alexis Perreault, Claudio Jeldres, Patrick P. McDonald, Claire M. Dubois
      Cancers.2021; 13(5): 1093.     CrossRef
    • The antitumor capacity of mesothelin-CAR-T cells in targeting solid tumors in mice
      Qian Zhang, Guoping Liu, Jibin Liu, Mu Yang, Juan Fu, Guodi Liu, Dehua Li, Zhangjie Gu, Linsong Zhang, Yingjiao Pan, Xingbing Cui, Lu Wang, Lixin Zhang, Xiaoli Tian
      Molecular Therapy - Oncolytics.2021; 20: 556.     CrossRef
    • EZH2 inhibition decreases neuroblastoma proliferation and in vivo tumor growth
      Laura V. Bownes, Adele P. Williams, Raoud Marayati, Laura L. Stafman, Hooper Markert, Colin H. Quinn, Nikita Wadhwani, Jamie M. Aye, Jerry E. Stewart, Karina J. Yoon, Elizabeth Mroczek-Musulman, Elizabeth A. Beierle, Joe W. Ramos
      PLOS ONE.2021; 16(3): e0246244.     CrossRef
    • Patient-derived xenograft models for the study of benign human neoplasms
      Juliana Cristina de Souza, Lucyene Miguita, Ricardo Santiago Gomez, Carolina Cavaliéri Gomes
      Experimental and Molecular Pathology.2021; 120: 104630.     CrossRef
    • Chromosome 8 gain is associated with high-grade transformation in MPNST
      Carina Dehner, Chang In Moon, Xiyuan Zhang, Zhaohe Zhou, Chris Miller, Hua Xu, Xiaodan Wan, Kuangying Yang, Jay Mashl, Sara J.C. Gosline, Yuxi Wang, Xiaochun Zhang, Abigail Godec, Paul A. Jones, Sonika Dahiya, Himanshi Bhatia, Tina Primeau, Shunqiang Li,
      JCI Insight.2021;[Epub]     CrossRef
    • Cancer models in preclinical research: A chronicle review of advancement in effective cancer research
      Humna Sajjad, Saiqa Imtiaz, Tayyaba Noor, Yusra Hasan Siddiqui, Anila Sajjad, Muhammad Zia
      Animal Models and Experimental Medicine.2021; 4(2): 87.     CrossRef
    • Rodent Models to Analyze the Glioma Microenvironment
      Susann Hetze, Ulrich Sure, Manfred Schedlowski, Martin Hadamitzky, Lennart Barthel
      ASN Neuro.2021; 13: 175909142110050.     CrossRef
    • Activity of Combined Androgen Receptor Antagonism and Cell Cycle Inhibition in Androgen Receptor Positive Triple Negative Breast Cancer
      Jessica L. Christenson, Kathleen I. O'Neill, Michelle M. Williams, Nicole S. Spoelstra, Kenneth L. Jones, G. Devon Trahan, Jordan Reese, Elaina T. Van Patten, Anthony Elias, Joel R. Eisner, Jennifer K. Richer
      Molecular Cancer Therapeutics.2021; 20(6): 1062.     CrossRef
    • Hexavalent TRAIL Fusion Protein Eftozanermin Alfa Optimally Clusters Apoptosis-Inducing TRAIL Receptors to Induce On-Target Antitumor Activity in Solid Tumors
      Darren C. Phillips, Fritz G. Buchanan, Dong Cheng, Larry R. Solomon, Yu Xiao, John Xue, Stephen K. Tahir, Morey L. Smith, Haichao Zhang, Deborah Widomski, Vivek C. Abraham, Nan Xu, Zhihong Liu, Li Zhou, Enrico DiGiammarino, Xin Lu, Nandini Rudra-Ganguly,
      Cancer Research.2021; 81(12): 3402.     CrossRef
    • Cloperastine inhibits esophageal squamous cell carcinoma proliferation in vivo and in vitro by suppressing mitochondrial oxidative phosphorylation
      Bo Li, Yin Yu, Yanan Jiang, Lili Zhao, Ang Li, Mingzhu Li, Baoyin Yuan, Jing Lu, Ziming Dong, Jimin Zhao, Kangdong Liu
      Cell Death Discovery.2021;[Epub]     CrossRef
    • Advanced Xenograft Model with Cotransplantation of Patient-Derived Organoids and Endothelial Colony-Forming Cells for Precision Medicine
      Junhye Kwon, Sungryong Oh, Misun Park, Joon Seog Kong, Sunyi Lee, Hyunsook Lee, Younjoo Kim, Kyu-Tae Kang, Ui Sup Shin, Joohee Jung, Muhammad Wasim Khan
      Journal of Oncology.2021; 2021: 1.     CrossRef
    • Human circular RNA hsa_circRNA_101705 (circTXNDC11) regulates renal cancer progression by regulating MAPK/ERK pathway
      Chong-Yi Yang, Jie Wang, Jian-Qiu Zhang, Hong-miao Cai
      Bioengineered.2021; 12(1): 4432.     CrossRef
    • A Review of Recent and Emerging Approaches for the Clinical Application of Cerenkov Luminescence Imaging
      Benedict Mc Larney, Magdalena Skubal, Jan Grimm
      Frontiers in Physics.2021;[Epub]     CrossRef
    • Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidates for targeted treatment
      Hua Sun, Song Cao, R. Jay Mashl, Chia-Kuei Mo, Simone Zaccaria, Michael C. Wendl, Sherri R. Davies, Matthew H. Bailey, Tina M. Primeau, Jeremy Hoog, Jacqueline L. Mudd, Dennis A. Dean, Rajesh Patidar, Li Chen, Matthew A. Wyczalkowski, Reyka G. Jayasinghe,
      Nature Communications.2021;[Epub]     CrossRef
    • Microdissected Tissue vs Tissue Slices—A Comparative Study of Tumor Explant Models Cultured On-Chip and Off-Chip
      Dina Dorrigiv, Kayla Simeone, Laudine Communal, Jennifer Kendall-Dupont, Amélie St-Georges-Robillard, Benjamin Péant, Euridice Carmona, Anne-Marie Mes-Masson, Thomas Gervais
      Cancers.2021; 13(16): 4208.     CrossRef
    • Patient-Derived Xenograft Models in Cervical Cancer: A Systematic Review
      Tomohito Tanaka, Ruri Nishie, Shoko Ueda, Shunsuke Miyamoto, Sousuke Hashida, Hiromi Konishi, Shinichi Terada, Yuhei Kogata, Hiroshi Sasaki, Satoshi Tsunetoh, Kohei Taniguchi, Kazumasa Komura, Masahide Ohmichi
      International Journal of Molecular Sciences.2021; 22(17): 9369.     CrossRef
    • Generation of Antibody-Drug Conjugate Resistant Models
      Lucía Gandullo-Sánchez, Alberto Ocaña, Atanasio Pandiella
      Cancers.2021; 13(18): 4631.     CrossRef
    • The Diverse Applications of Pancreatic Ductal Adenocarcinoma Organoids
      Ronnie Ren Jie Low, Wei Wen Lim, Paul M. Nguyen, Belinda Lee, Michael Christie, Antony W. Burgess, Peter Gibbs, Sean M. Grimmond, Frédéric Hollande, Tracy L. Putoczki
      Cancers.2021; 13(19): 4979.     CrossRef
    • Methodological aspects of creation of patient-derived tumor xenografts
      A S Goncharova, A N Shevchenko, I R Dashkova, A E Anisimov
      Kazan medical journal.2021; 102(5): 694.     CrossRef
    • Preclinical Models and Resources to Facilitate Basic Science Research on Malignant Mesothelioma – A Review
      Ben William Johnson, Ken Takahashi, Yuen Yee Cheng
      Frontiers in Oncology.2021;[Epub]     CrossRef
    • A novel PDX modeling strategy and its application in metabolomics study for malignant pleural mesothelioma
      Zhongjian Chen, Chenxi Yang, Zhenying Guo, Siyu Song, Yun Gao, Ding Wang, Weimin Mao, Junping Liu
      BMC Cancer.2021;[Epub]     CrossRef
    • Discovery of Novel Polycyclic Heterocyclic Derivatives from Evodiamine for the Potential Treatment of Triple-Negative Breast Cancer
      Shengtao Xu, Hong Yao, Yangyi Qiu, Manzhen Zhou, Dahong Li, Liang Wu, Dong-Hua Yang, Zhe-Sheng Chen, Jinyi Xu
      Journal of Medicinal Chemistry.2021; 64(23): 17346.     CrossRef
    • Preclinical Models for the Study of Lung Cancer Pathogenesis and Therapy Development
      Anna Arnal-Estapé, Giorgia Foggetti, Jacqueline H. Starrett, Don X. Nguyen, Katerina Politi
      Cold Spring Harbor Perspectives in Medicine.2021; 11(12): a037820.     CrossRef
    • Patient-Derived Xenografts of High-Grade Serous Ovarian Cancer Subtype as a Powerful Tool in Pre-Clinical Research
      Magdalena Cybula, Lin Wang, Luyao Wang, Ana Luiza Drumond-Bock, Katherine M. Moxley, Doris M. Benbrook, Camille Gunderson-Jackson, Maria J. Ruiz-Echevarria, Resham Bhattacharya, Priyabrata Mukherjee, Magdalena Bieniasz
      Cancers.2021; 13(24): 6288.     CrossRef
    • NSG mice as hosts for oncological precision medicine
      Claudia Maletzki, Stephanie Bock, Philipp Fruh, Karolis Macius, Anika Witt, Friedrich Prall, Michael Linnebacher
      Laboratory Investigation.2020; 100(1): 27.     CrossRef
    • Circulating tumor cell as the functional aspect of liquid biopsy to understand the metastatic cascade in solid cancer
      Luis Enrique Cortés-Hernández, Zahra Eslami-S, Catherine Alix-Panabières
      Molecular Aspects of Medicine.2020; 72: 100816.     CrossRef
    • Modelling of pancreatic cancer biology: transcriptomic signature for 3D PDX-derived organoids and primary cell line organoid development
      Shannon R. Nelson, Chenxi Zhang, Sandra Roche, Fiona O’Neill, Niall Swan, Yonglun Luo, AnneMarie Larkin, John Crown, Naomi Walsh
      Scientific Reports.2020;[Epub]     CrossRef
    • Lenvatinib for thyroid cancer treatment: discovery, pre-clinical development and clinical application
      Rosa Maria Paragliola, Andrea Corsello, Valeria Del Gatto, Giampaolo Papi, Alfredo Pontecorvi, Salvatore Maria Corsello
      Expert Opinion on Drug Discovery.2020; 15(1): 11.     CrossRef
    • Modeling the Tumor Microenvironment and Pathogenic Signaling in Bone Sarcoma
      Eric R. Molina, Letitia K. Chim, Sergio Barrios, Joseph A. Ludwig, Antonios G. Mikos
      Tissue Engineering Part B: Reviews.2020; 26(3): 249.     CrossRef
    • Organoid of ovarian cancer: genomic analysis and drug screening
      H.-D. Liu, B.-R. Xia, M.-Z. Jin, G. Lou
      Clinical and Translational Oncology.2020; 22(8): 1240.     CrossRef
    • Mouse models of thyroid cancer: Bridging pathogenesis and novel therapeutics
      Yuchen Jin, Min Liu, Ri Sa, Hao Fu, Lin Cheng, Libo Chen
      Cancer Letters.2020; 469: 35.     CrossRef
    • Pediatric Cancer Models in Zebrafish
      Mattie J. Casey, Rodney A. Stewart
      Trends in Cancer.2020; 6(5): 407.     CrossRef
    • Three‐dimensional in vitro cell culture devices using patient‐derived cells for high‐throughput screening of drug combinations
      Seok‐Joon Kwon, Dongwoo Lee, Sneha Gopal, Ashlyn Ku, Hosang Moon, Jonathan S. Dordick
      MEDICAL DEVICES & SENSORS.2020;[Epub]     CrossRef

    • The Use of Molecular Subtypes for Precision Therapy of Recurrent and Metastatic Gastrointestinal Stromal Tumor


      Peng Liu, Fengbo Tan, Heli Liu, Bin Li, Tianxiang Lei, Xianhui Zhao
      OncoTargets and Therapy.2020; Volume 13: 2433.     CrossRef
    • The Biology of Malignant Mesothelioma and the Relevance of Preclinical Models
      Christophe Blanquart, Marie-Claude Jaurand, Didier Jean
      Frontiers in Oncology.2020;[Epub]     CrossRef
    • Establishment and Characterisation of Heterotopic Patient-Derived Xenografts for Glioblastoma
      Sarah Meneceur, Annett Linge, Matthias Meinhardt, Sandra Hering, Steffen Löck, Rebecca Bütof, Dietmar Krex, Gabriele Schackert, Achim Temme, Michael Baumann, Mechthild Krause, Cläre von Neubeck
      Cancers.2020; 12(4): 871.     CrossRef
    • The humanized mouse: Emerging translational potential
      J. Jason Morton, Nathaniel Alzofon, Antonio Jimeno
      Molecular Carcinogenesis.2020; 59(7): 830.     CrossRef
    • Establishment and characterization of a cell line and patient-derived xenograft (PDX) from peritoneal metastasis of low-grade serous ovarian carcinoma
      Elien De Thaye, Koen Van de Vijver, Joni Van der Meulen, Joachim Taminau, Glenn Wagemans, Hannelore Denys, Jo Van Dorpe, Geert Berx, Wim Ceelen, Jan Van Bocxlaer, Olivier De Wever
      Scientific Reports.2020;[Epub]     CrossRef
    • Update on in-vivo preclinical research models in adrenocortical carcinoma
      Adwitiya Kar, Margaret E. Wierman, Katja Kiseljak-Vassiliades
      Current Opinion in Endocrinology, Diabetes & Obesity.2020; 27(3): 170.     CrossRef
    • Establishment of patient-derived xenografts from patients with gastrointestinal stromal tumors: analysis of clinicopathological characteristics related to engraftment success
      Young-Soon Na, Min-Hee Ryu, Young Soo Park, Chae-Won Lee, Ju-Kyung Lee, Yangsoon Park, Jung Min Park, Jungeun Ma, Yoon-Koo Kang
      Scientific Reports.2020;[Epub]     CrossRef
    • Genetic Alterations Featuring Biological Models to Tailor Clinical Management of Pancreatic Cancer Patients
      Shannon R. Nelson, Naomi Walsh
      Cancers.2020; 12(5): 1233.     CrossRef
    • Patient-derived xenografts as compatible models for precision oncology
      Sung-Yup Cho
      Laboratory Animal Research.2020;[Epub]     CrossRef
    • Emerging Challenges of Preclinical Models of Anti-tumor Immunotherapeutic Strategies Utilizing Vγ9Vδ2 T Cells
      Noémie Joalland, Emmanuel Scotet
      Frontiers in Immunology.2020;[Epub]     CrossRef
    • Comparing the fate of brain metastatic breast cancer cells in different immune compromised mice with cellular magnetic resonance imaging
      Natasha N. Knier, Amanda M. Hamilton, Paula J. Foster
      Clinical & Experimental Metastasis.2020; 37(4): 465.     CrossRef
    • Solid Composite Material for Delivering Viable Cells into Skin Tissues via Detachable Dissolvable Microneedles
      Puttikorn Pukfukdee, Wijit Banlunara, Teeranut Rutwaree, Benchaphorn Limcharoen, Pritsana Sawutdeechaikul, Thitiporn Pattarakankul, Titiporn Sansureerungsikul, Pattrawadee Toprangkobsin, Asada Leelahavanichkul, Ratchathorn Panchaprateep, Pravit Asawanonda
      ACS Applied Bio Materials.2020; 3(7): 4581.     CrossRef
    • Establishing metastatic patient-derived xenograft model for colorectal cancer
      Yanmei Zhang, Sau Har Lee, Cheng Wang, Yunhe Gao, Jiyang Li, Wei Xu
      Japanese Journal of Clinical Oncology.2020; 50(10): 1108.     CrossRef
    • Intestinal stem cells and intestinal organoids
      Qian Zhao, Jiawei Guan, Xia Wang
      Journal of Genetics and Genomics.2020;[Epub]     CrossRef
    • Identification of Tumor Antigens in the HLA Peptidome of Patient-derived Xenograft Tumors in Mouse
      Nataly Mancette Rijensky, Netta R. Blondheim Shraga, Eilon Barnea, Nir Peled, Eli Rosenbaum, Aron Popovtzer, Solomon M. Stemmer, Alejandro Livoff, Mark Shlapobersky, Neta Moskovits, Dafna Perry, Eitan Rubin, Itzhak Haviv, Arie Admon
      Molecular & Cellular Proteomics.2020; 19(8): 1360.     CrossRef
    • Head and neck cancer patient-derived xenograft models – A systematic review
      Lauren F. Schuch, Felipe M. Silveira, Vivian P. Wagner, Gabriell B. Borgato, Guilherme Z. Rocha, Rogerio M. Castilho, Pablo A. Vargas, Manoela D. Martins
      Critical Reviews in Oncology/Hematology.2020; 155: 103087.     CrossRef
    • ZenoFishDb v1.1: A Database for Xenotransplantation Studies in Zebrafish
      Seniye Targen, Tuğberk Kaya, M. Ender Avci, Damla Gunes, Ayse Gokce Keskus, Ozlen Konu
      Zebrafish.2020; 17(5): 305.     CrossRef
    • Powerful quantifiers for cancer transcriptomics
      Dumitru Andrei Iacobas
      World Journal of Clinical Oncology.2020; 11(9): 679.     CrossRef
    • Three-Dimensional Culture Systems in Gastric Cancer Research
      George Alzeeb, Jean-Philippe Metges, Laurent Corcos, Catherine Le Jossic-Corcos
      Cancers.2020; 12(10): 2800.     CrossRef
    • Autologous culture method improves retention of tumors’ native properties
      Yao Tang, Qian Xu, Meiling Yan, Yimin Zhang, Ping Zhu, Xianghong Li, Limin Sang, Ming Zhang, Wenhe Huang, Lianxing Lin, Jundong Wu, Yue Xin, Junhui Fu, Li Zhang, Shuming Zhang, Jiang Gu
      Scientific Reports.2020;[Epub]     CrossRef
    • Organoid Cultures as Preclinical Models of Non–Small Cell Lung Cancer
      Ruoshi Shi, Nikolina Radulovich, Christine Ng, Ni Liu, Hirotsugu Notsuda, Michael Cabanero, Sebastiao N. Martins-Filho, Vibha Raghavan, Quan Li, Arvind Singh Mer, Joshua C. Rosen, Ming Li, Yu-Hui Wang, Laura Tamblyn, Nhu-An Pham, Benjamin Haibe-Kains, Geo
      Clinical Cancer Research.2020; 26(5): 1162.     CrossRef
    • A Proof of Concept for Biomarker-Guided Targeted Therapy against Ovarian Cancer Based on Patient-Derived Tumor Xenografts
      Adam C. Palmer, Deborah Plana, Hui Gao, Joshua M. Korn, Guizhi Yang, John Green, Xiamei Zhang, Roberto Velazquez, Margaret E. McLaughlin, David A. Ruddy, Colleen Kowal, Julie Muszynski, Caroline Bullock, Stacy Rivera, Daniel P. Rakiec, GiNell Elliott, Pau
      Cancer Research.2020; 80(19): 4278.     CrossRef
    • Establishment of a Novel PDX Mouse Model and Evaluation of the Tumor Suppression Efficacy of Bortezomib Against Liposarcoma
      Eun Byeol Jo, Doopyo Hong, Young Sang Lee, Hyunjoo Lee, Jae Berm Park, Sung Joo Kim
      Translational Oncology.2019; 12(2): 269.     CrossRef
    • DNA G-quadruplexes binding and antitumor activity of palladium aryl oxime ligand complexes encapsulated in either albumin or algal cellulose nanoparticles
      Nazanin Hashemzadeh Esfahani, Fatemeh Salami, Zeinab Saberi, Kazem Karami, Zohreh Mehri Lighvan, Mohammad Ramezani, Mona Alibolandi, Sara Amel Farzad, Taghi Khayamian
      Colloids and Surfaces B: Biointerfaces.2019; 176: 70.     CrossRef
    • Tumor Tissue Explant Culture of Patient-Derived Xenograft as Potential Prioritization Tool for Targeted Therapy
      Susmita Ghosh, Manu Prasad, Kiran Kundu, Limor Cohen, Ksenia M. Yegodayev, Jonathan Zorea, Ben-Zion Joshua, Batel Lasry, Orr Dimitstein, Anat Bahat-Dinur, Aviram Mizrachi, Vladimir Lazar, Moshe Elkabets, Angel Porgador
      Frontiers in Oncology.2019;[Epub]     CrossRef
    • Epithelial-mesenchymal transition as a mechanism of resistance to tyrosine kinase inhibitors in clear cell renal cell carcinoma
      Hee Sang Hwang, Heounjeong Go, Ja-Min Park, Sun Young Yoon, Jae-Lyun Lee, Se Un Jeong, Yong Mee Cho
      Laboratory Investigation.2019; 99(5): 659.     CrossRef
    • Systematic Generation of Patient-Derived Tumor Models in Pancreatic Cancer
      Karl Roland Ehrenberg, Jianpeng Gao, Felix Oppel, Stephanie Frank, Na Kang, Tim Kindinger, Sebastian M. Dieter, Friederike Herbst, Lino Möhrmann, Taronish D. Dubash, Erik R. Schulz, Hendrik Strakerjahn, Klara M. Giessler, Sarah Weber, Ava Oberlack, Eva-Ma
      Cells.2019; 8(2): 142.     CrossRef
    • Integrative In Vivo Drug Testing Using Gene Expression Signature and Patient-Derived Xenografts from Treatment-Refractory HER2 Positive and Triple-Negative Subtypes of Breast Cancer
      Jin-Sun Ryu, Sung Hoon Sim, In Hae Park, Eun Gyeong Lee, Eun Sook Lee, Yun-Hee Kim, Youngmee Kwon, Sun-Young Kong, Keun Seok Lee
      Cancers.2019; 11(4): 574.     CrossRef
    • Transplantable zebrafish models of neuroendocrine tumors
      Germano Gaudenzi, Giovanni Vitale
      Annales d'Endocrinologie.2019; 80(3): 149.     CrossRef
    • Patient Derived Chicken Egg Tumor Model (PDcE Model): Current Status and Critical Issues
      Aoi Komatsu, Kotaro Matsumoto, Tomoki Saito, Manabu Muto, Fuyuhiko Tamanoi
      Cells.2019; 8(5): 440.     CrossRef
    • Establishment of Highly Transplantable Cholangiocarcinoma Cell Lines from a Patient-Derived Xenograft Mouse Model
      Kulthida Vaeteewoottacharn, Chawalit Pairojkul, Ryusho Kariya, Kanha Muisuk, Kanokwan Imtawil, Yaovalux Chamgramol, Vajarabhongsa Bhudhisawasdi, Narong Khuntikeo, Ake Pugkhem, O-Tur Saeseow, Atit Silsirivanit, Chaisiri Wongkham, Sopit Wongkham, Seiji Okad
      Cells.2019; 8(5): 496.     CrossRef
    • Un nouveau modèle animal d’étude du neuroblastome
      V. Castellani
      Bulletin de l'Académie Nationale de Médecine.2019; 203(5): 321.     CrossRef
    • Glioblastoma stem cells: lessons from the tumor hierarchy in a lethal cancer
      Ryan C. Gimple, Shruti Bhargava, Deobrat Dixit, Jeremy N. Rich
      Genes & Development.2019; 33(11-12): 591.     CrossRef
    • Assessment of Copper Nanoclusters for Accurate in Vivo Tumor Imaging and Potential for Translation
      Gyu Seong Heo, Yongfeng Zhao, Deborah Sultan, Xiaohui Zhang, Lisa Detering, Hannah P. Luehmann, Xiangyu Zhang, Richen Li, Ankur Choksi, Savannah Sharp, Sidney Levingston, Tina Primeau, David E. Reichert, Guorong Sun, Babak Razani, Shunqiang Li, Katherine
      ACS Applied Materials & Interfaces.2019; 11(22): 19669.     CrossRef
    • Establishment of Novel Gastric Cancer Patient-Derived Xenografts and Cell Lines: Pathological Comparison between Primary Tumor, Patient-Derived, and Cell-Line Derived Xenografts
      Takeshi Kuwata, Kazuyoshi Yanagihara, Yuki Iino, Teruo Komatsu, Atsushi Ochiai, Shigeki Sekine, Hirokazu Taniguchi, Hitoshi Katai, Takahiro Kinoshita, Atsushi Ohtsu
      Cells.2019; 8(6): 585.     CrossRef
    • MicroSPECT/CT Imaging of Cell-Line and Patient-Derived EGFR-Positive Tumor Xenografts in Mice with Panitumumab Fab Modified with Hexahistidine Peptides To Enable Labeling with 99mTc(I) Tricarbonyl Complex
      Anthony Ku, Conrad Chan, Sadaf Aghevlian, Zhongli Cai, David Cescon, Scott V. Bratman, Laurie Ailles, David W. Hedley, Raymond M. Reilly
      Molecular Pharmaceutics.2019; 16(8): 3559.     CrossRef
    • Human organotypic brain slice culture: a novel framework for environmental research in neuro-oncology
      Vidhya M Ravi, Kevin Joseph, Julian Wurm, Simon Behringer, Nicklas Garrelfs, Paolo d’ Errico, Yashar Naseri, Pamela Franco, Melanie Meyer-Luehmann, Roman Sankowski, Mukesch Johannes Shah, Irina Mader, Daniel Delev, Marie Follo, Jürgen Beck, Oliver Schnell
      Life Science Alliance.2019; 2(4): e201900305.     CrossRef
    • Pregnancy and Breast Cancer: Pathways to Understand Risk and Prevention
      Priscila F. Slepicka, Samantha L. Cyrill, Camila O. dos Santos
      Trends in Molecular Medicine.2019; 25(10): 866.     CrossRef
    • Primary Tumor Site Specificity is Preserved in Patient-Derived Tumor Xenograft Models
      Lei Chen, Xiaoyong Pan, Yu-Hang Zhang, Xiaohua Hu, KaiYan Feng, Tao Huang, Yu-Dong Cai
      Frontiers in Genetics.2019;[Epub]     CrossRef
    • The promises and challenges of patient‐derived tumor organoids in drug development and precision oncology
      Lauren M. Granat, Ooha Kambhampati, Stephanie Klosek, Brian Niedzwecki, Kian Parsa, Dong Zhang
      Animal Models and Experimental Medicine.2019; 2(3): 150.     CrossRef
    • Bone sarcoma patient-derived xenografts are faithful and stable preclinical models for molecular and therapeutic investigations
      Patrizia Nanni, Lorena Landuzzi, Maria Cristina Manara, Alberto Righi, Giordano Nicoletti, Camilla Cristalli, Michela Pasello, Alessandro Parra, Marianna Carrabotta, Manuela Ferracin, Arianna Palladini, Marianna L. Ianzano, Veronica Giusti, Francesca Ruzz
      Scientific Reports.2019;[Epub]     CrossRef
    • Scaffold-Assisted Ectopic Transplantation of Internal Organs and Patient-Derived Tumors
      Ryan Carpenter, Hye Jeong Oh, In-Hye Ham, Daeyoung Kim, Hoon Hur, Jungwoo Lee
      ACS Biomaterials Science & Engineering.2019; 5(12): 6667.     CrossRef
    • Generation and application of patient-derived xenograft models in pancreatic cancer research
      Cheng-Fang Wang, Xian-Jie Shi
      Chinese Medical Journal.2019; 132(22): 2729.     CrossRef
    • Focal Adhesion Kinase Inhibition Contributes to Tumor Cell Survival and Motility in Neuroblastoma Patient-Derived Xenografts
      Laura L. Stafman, Adele P. Williams, Raoud Marayati, Jamie M. Aye, Hooper R. Markert, Evan F. Garner, Colin H. Quinn, Shoeb B. Lallani, Jerry E. Stewart, Karina J. Yoon, Kimberly Whelan, Elizabeth A. Beierle
      Scientific Reports.2019;[Epub]     CrossRef
    • Biomarkers and Preclinical Models for Adult T-Cell Leukemia-Lymphoma Treatment
      Lee Ratner
      Frontiers in Microbiology.2019;[Epub]     CrossRef
    • Integrative Pharmacogenomics Analysis of Patient-Derived Xenografts
      Arvind S. Mer, Wail Ba-Alawi, Petr Smirnov, Yi X. Wang, Ben Brew, Janosch Ortmann, Ming-Sound Tsao, David W. Cescon, Anna Goldenberg, Benjamin Haibe-Kains
      Cancer Research.2019; 79(17): 4539.     CrossRef
    • COMMD3:BMI1 Fusion and COMMD3 Protein Regulate C-MYC Transcription: Novel Therapeutic Target for Metastatic Prostate Cancer
      Syed Umbreen, Mudassir Meraj Banday, Anmbreen Jamroze, Adrian P. Mansini, Arsheed A. Ganaie, Marina G. Ferrari, Raihana Maqbool, Firdous H. Beigh, Paari Murugan, Colm Morrissey, Eva Corey, Badrinath R. Konety, Mohammad Saleem
      Molecular Cancer Therapeutics.2019; 18(11): 2111.     CrossRef
    • Galangin’s potential as a functional food ingredient
      Kit-Kay Mak, Joe-Jen Tan, Puvaneswari Marappan, Madhu Katyayani Balijepalli, Hira Choudhury, Srinivasan Ramamurthy, Mallikarjuna Rao Pichika
      Journal of Functional Foods.2018; 46: 490.     CrossRef
    • Patient-Derived Xenograft Models for Endometrial Cancer Research
      Cristian Moiola, Carlos Lopez-Gil, Silvia Cabrera, Angel Garcia, Tom Van Nyen, Daniela Annibali, Tina Fonnes, August Vidal, Alberto Villanueva, Xavier Matias-Guiu, Camilla Krakstad, Frédéric Amant, Antonio Gil-Moreno, Eva Colas
      International Journal of Molecular Sciences.2018; 19(8): 2431.     CrossRef
    • Tumor xenograft animal models for esophageal squamous cell carcinoma
      Nikki P. Lee, Chung Man Chan, Lai Nar Tung, Hector K. Wang, Simon Law
      Journal of Biomedical Science.2018;[Epub]     CrossRef
    • Roles of the immune system in cancer: from tumor initiation to metastatic progression
      Hugo Gonzalez, Catharina Hagerling, Zena Werb
      Genes & Development.2018; 32(19-20): 1267.     CrossRef
    • Adipocyte-derived IL-6 and leptin promote breast Cancer metastasis via upregulation of Lysyl Hydroxylase-2 expression
      Jin-Yong He, Xiao-Hui Wei, Si-Jing Li, Yang Liu, Hao-Lin Hu, Zheng-Zheng Li, Xin-Hong Kuang, Lai Wang, Xin Shi, Sheng-Tao Yuan, Li Sun
      Cell Communication and Signaling.2018;[Epub]     CrossRef
    • Chick chorioallantoic membrane assay as an in vivo model to study the effect of nanoparticle-based anticancer drugs in ovarian cancer
      Binh Thanh Vu, Sophia Allaf Shahin, Jonas Croissant, Yevhen Fatieiev, Kotaro Matsumoto, Tan Le-Hoang Doan, Tammy Yik, Shirleen Simargi, Altagracia Conteras, Laura Ratliff, Chiara Mauriello Jimenez, Laurence Raehm, Niveen Khashab, Jean-Olivier Durand, Carl
      Scientific Reports.2018;[Epub]     CrossRef
    • Patient derived xenografts (PDX) predict an effective heparanase-based therapy for lung cancer
      Amit Katz, Uri Barash, Ilanit Boyango, Sari Feld, Yaniv Zohar, Edward Hammond, Neta Ilan, Ran Kremer, Israel Vlodavsky
      Oncotarget.2018; 9(27): 19294.     CrossRef

    • PubReader PubReader
    • ePub LinkePub Link
    • Cite
      CITE
      export Copy Download
      Close
      Download Citation
      Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.
      Format:
      • RIS — For EndNote, ProCite, RefWorks, and most other reference management software
      • BibTeX — For JabRef, BibDesk, and other BibTeX-specific software
      Include:
      • Citation for the content below
      The Generation and Application of Patient-Derived Xenograft Model for Cancer Research
      Cancer Res Treat. 2018;50(1):1-10.   Published online September 13, 2017
      DOI: https://doi.org/10.4143/crt.2017.307
      Close
    • XML DownloadXML Download
    Figure
    • 0
    • 1
    Related articles
    The Generation and Application of Patient-Derived Xenograft Model for Cancer Research
    Image Image
    Fig. 1. An overall procedure for the generation of patient-derived xenograft (PDX) model. The PDX model can be developed by the implantation of fragments from a patient’s tumor into an immunodeficient mouse directly. A part of tumor from surgery (breast or pancreatic tumor in this example) is put in preserving media and the tumor is sliced into small fragments. The fragments are implanted subcutaneously or into the orthotopical organ, for example, mammary fat pad in the case of breast cancer.
    Fig. 2. A flowchart showing the establishment of personalized medicine using patient-derived xenograft (PDX) model. Genomic signature of a primary tumor is analyzed by next-generation sequencing. At the same time, tumor fragments are implanted into immunodeficient mouse. The patient will be treated with the drug that showed best response in PDX. Also, a database of integrated genomic signature would be established to predict a drug response for a new patient with similar genomic signature. SNP, single nucleotide polymorphism.

    Fig. 1.

    Fig. 2.

    The Generation and Application of Patient-Derived Xenograft Model for Cancer Research
    Mouse strain Deficiency Median survival Advantage Disadvantage
    Nude No functional T cell Not determined Well characterized Functional B and NK cell
    High take-rate of human tumor T-cell functionality increases with age
    Not suitable for primary cell transplantation
    SCID No functional T and B cell Not determined Better engrafment of allogeneic and xenogeneic tumor cells and tissues than in nude strain Functional NK cells
    Spontaneous lymphomas
    NOD-SCID No functional T and B cell 36 wk Low NK cell activity High incidence of lymphomas
    NK cell impaired Very low leakiness with age Radiosensitive
    Engrafts hematopoietic cancer cell line
    NSG No functional T, B, and NK cell > 89 wk Lymphoma-resistant excellent engraftment of allogeneic and xenogeneic tumor cells and tissue Not well charaterized
    Suitable for analysis of human cancer stem cells and metastasis
    Tumor type Available model Mice strain Implantation site Engraftment rate (%) Reference
    Colorectal cancer 130 NOD/SCID s.c. 87 [18]
    Colorectal cancer 54 Nude s.c. 64 [19]
    Colorectal cancer 41 Nude Orthotopic 89 [20]
    Breast cancer 25 Nude s.c. 13 [21]
    Breast cancer 12 NOD/SCID with estrogen supplementation for ER+ tumors Mammary fat pad 27 [22]
    NSCLC 25 NOD/SCID s.c. 25 [23]
    NSCLC 32 NOD/SCID Renal capsule 90 [24]
    Pancreatic ductal carcinoma 42 Nude s.c. 61 [25]
    Pancreatic ductal carcinoma 16 Nude Orthotopic 62 [26]
    SCCHN 22 NSG s.c. 85 [27]
    SCCHN/SCC 21 Nude s.c. 54 [28]
    Uveal melanoma 25 NOD/SCID s.c. 28 [29]
    Gastric cancer 15 Nude and NOG s.c. 24 [30]
    Ovarian cancer 29 NSG i.p. 31 [31]
    Prostate cancer 31 NOD/SCID Subrenal capsule 95 [32]
    Renal cell carcinoma 30 Nude s.c. 8.9 [33]
    Table 1. Summary of advantages/disadvantages of immune-deficient mouse strains for PDX

    PDX, patient-derived xenograft; NK, natural killer; SCID, severely compromised immune deficient; NOD, nonobese diabetic; NSG, NOD-SCID mice with IL-2Rnull.

    Table 2. Success rate of PDX for various type of cancers grafted on different sites and strains

    PDX, patient-derived xenograft; NOD, nonobese diabetic; SCID, severely compromised immune deficient; s.c., subcutaneous; ER, estrogen receptor; NSCLC, non-small cell lung cancer; SCCHN, squamous cell carcinoma of the head and neck; NSG, NOD-SCID mice with IL-2Rnull; SCC, squamous cell carcinoma; NOG, NOD-SCID mice with c null; i.p., intraperitoneal.

    Table 1.

    Table 2.

    Cancer Res Treat : Cancer Research and Treatment
    © Korean Cancer Association.
    Close layer
    TOP